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ABSTRACT
 
BACKGROUND: obesity may be associated with a later onset of chronic 
disorders and clinical complications. Insulin resistance, glucose intolerance 
and hyperinsulinemia are major components of the metabolic syndrome, 
which is highly prevalent among children and adolescents with severe 
obesity. Low levels of LCPUFAs, especially docosahexaenoic acid (C22:6 
n-3, [DHA]) and a high n-6/n-3 LCPUFA ratio in skeletal muscle membrane 
phospholipids have been associated with insulin resistance in adults. Recent 
data suggest that the synthesis of DHA differs between obese children 
and normal weight children. In particular, in obese children, the highest 
quartile of BMI z-score was associated with higher plasma levels of the 
n-6/n-3 LCPUFA ratio. Given the high prevalence of insulin resistance in 
childhood obesity, we asked whether supplementation with DHA would be 
more effective than diet and physical activity alone in reducing this metabolic 
alteration. 
AIM: to determine whether DHA supplementation, in addition to adequate 
diet and lifestyle, may reduce insulin resistance compared with diet and 
physical activity only, in obese children. Secondary aims were to evaluate 
whether may exist an association of the change of steatosis degree after the 
intervention with DHA supplementation...
SUBJECTS AND METHODS: this is a multicenter, longitudinal, double-blind, 
randomized, placebo-controlled trial that started on January 01, 2010. 
Up to September 30, 2012, thirty (14 boys, 16 girls, mean [SD] age, 11.4 
[1.29] years, range 8-13), were recruited. All obese children consecutively 
admitted to the Department of Paediatrics, San Paolo Hospital, Milan, and 
to the Department of Paediatrics, Federico II Hospital, Naples, for routine 
examinations were assessed for eligibility.  The study protocol scheduled 
daily oral supplementation of either an intervention “product”, that is two 
capsule of purified DHA (500 mg) or two capsule of wheat germ oil (500 
mg). A nutritional-behavioural intervention was additionally recommended in 
all recruited children promoting a normocaloric balanced diet and an active 
lifestyle based on the Italian guidelines for treatment of childhood obesity. 
Additional recommendations were given to engage in a moderate daily 
exercise program (30-45 minutes/day aerobic physical exercise), tailored to 
individual preferences.   Children were visited at the care centers within 3±1 
days (baseline) after enrolment, and at 6 months after starting intervention. 
Evaluations included anthropometrical measurements, nutritional, metabolic 
assessment and liver ultrasonography.
 
Children were randomly assigned to the intervention or control group based 
on a computer generated, blocked randomization list by each center. A block 
size of four was used, stratified according to gender. The investigator who 
generated the randomization sequence was independent of the research 
staff and unaware of children. 
RESULTS: at baseline there was no significant difference between groups for 
any anthropometrical (minimum P≤ 0.806) or dietary (minimum P≤ 0.318) or 
biochemical (minimum P≤ 0.539) variable.
No significant difference among groups occurred for daily intake of energy or 
any macronutrient and the end of the study (minimum P=0.111). 
At the end of the intervention a significant reduction of plasma fasting glucose 
(DHA group P=0.046; placebo group P=0.048), insulin (DHA group P=0.001; 
placebo group P=0.048) and HOMA (DHA group P=0.001; placebo group 
P=0.050) in both groups was observed. A higher percentage variation of 
plasma fasting insulin (P=0.0046) and HOMA (P=0.0045) in DHA than 
placebo group was showed.
There was a difference between groups for percentage reduction of liver 
steatosis: in DHA group from 14 to 7 % (P=0.655), in placebo group from 20 
to 13 % (P=0.275). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0. PRELIMINARY REMARKS AND EPIDEMIOLOGY
In the last two decades overweight and obesity prevalence showed an 
exponential increase throughout the world, in the population in general and 
specifically at paediatric age. For this reason it is now defined as one of 
the most important health and medical issues of our times. The neologism 
“globesity” was created to indicate the worldwide diffusion of this phenomenon 
(Ebbeling CB et al., 2002). 
In many European countries, in the last 30 years obesity levels trebled: 25 - 
79% of adults are considered overweight and 5 – 30% obese, depending on 
the specific country of origin. Youth obesity specifically is currently ten times 
higher than in the 1970s (Skelton JA et al., 2009): 20% of European children 
are overweight with peaks of 33-34% for the age between 6 and 9, a third of 
these children are obese (the World Health Organization [WHO], 2012). 
In Italy the 2009 ISTAT survey “Aspetti della vita Quotidiana” (Aspects 
of everyday life) showed that during the period 2001-2009 overweight 
and obesity diffusion had an increase. Specifically, there was a shift from 
the 33.9% of 2001 to the 36.1% in 2009 of people overweight, and from 
the 8.5% of 2001 to the 10.3% of 2009 of people considered obese. As 
far as childhood obesity in Italy is concerned, an epidemiological survey 
carried out by the Ministry of Health in 2008 and in 2010 to promote health 
and healthy development for primary school children “Okkio alla Salute” 
(Okkio to health) which involved over 42.000 children from the third class of 
primary schools (age 8-9), showed that overweight and obesity prevalence 
is of 22.9% for overweight and of 11.1% for obesity, thus confirming the 
European data (Istituto Superiore di Sanità- Rapporti ISTISAN: 09/24- Roma 
2009). Furthermore the survey allowed verifying an important geographical 
variability, with overweight-obesity percentages which lower in the Northern 
regions in comparison to those of the South. The trend proved to be the 
same for children and adults alike (Figures 1 and 2). 
 
 
 
 
 
 
 
 
 
FIGURE 1. Overweight-obesity percentages of children from the third class 
of primary schools (age 8-9) in the Northern and South regions of Italy (2008-
 
2009). Source: “Okkio alla Salute”, 2008-2009 (Ministry of Health, Rome, 
Italy)
 
 
FIGURE 2. Overweight-obesity percentages of children from the third class of 
primary schools (age 8-9) in the Northern and South regions of Italy (2010). 
Source: “Okkio alla Salute”, 2010 (Ministry of Health, Rome, Italy)
 
 
The interest concerning the pathology, besides the prevalence issue, is 
connected to the renowned link between obesity and other important risk 
 
factors for cardiovascular pathologies such as arterial hypertension (AHT), 
glucose intolerance or insulin-resistance and dyslipidemia. Indeed the 
latter disorders constitute the clinical picture defined metabolic syndrome 
which is the clinical picture recognized as being the main mortality cause in 
industrialized countries (Lau DC et al., 2007; Park MH et al., 2012). 
For paediatric age too, scientific literature highlights the risks for future 
pathologies, the negative effects on psychological and relational 
development. Finally it was also pointed out how the presence of overweight 
and obesity, of an adiposity rebound at around the age of five and an obese 
parent represent risk factors for a persistent obesity in the future (Kuhl ES et 
al., 2012). 
Nowadays, obesity is still one of the most complex and lesser understood 
diseases, so frequent yet so refractory to treatment (Ebbeling CB et al., 
2002); indeed there are no effective medical-surgical therapies to treat 
obesity at paediatric age and weight-reducing diets and pharmacotherapy 
used for adults are greatly debated. 
The limited successes of therapies and the severe complications connected 
to excess weight and obesity require a pre-emptive intervention on the 
population. Therefore prevention strategies and medical education to reduce 
nutritional excesses, to improve food-related habits and to foster a more 
adequate life style, for children as well as for whole families, gain primary 
importance. 
These interventions prove to be more worthwhile when carried out at 
paediatric age, thus justifying the commitment to create prevention programs 
concerning over weight and obesity since infancy (Drake KM et al., 2012). 
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1. DEFINITION
Obesity is a clinical condition characterized by an excess of body fat, caused 
by a disorder of energy metabolism, which is marked by an imbalance 
between the intake and the expenditure of energy, with an accumulation of 
excess calories as triglycerides in the adypocites. Such imbalance can derive 
from an excessive caloric intake, from reduced energy expenditure, or from 
an alteration of the mechanisms regulating energy balance. The tool currently 
in use to define the condition of overweight and of obesity, for the child as 
well as for the adult, is the Body Mass Index (BMI) (Krebs NF & Jacobson 
MS, 2003) which is calculated dividing the weight (kg) by the squared height 
(m2). For adulthood there are thresholds values, within which the levels of 
overweight and of obesity are defined, as shown in table 1. It is not possible 
to apply the same threshold values for childhood due to the continuous 
variation of height during growth (Ludwig DS, 2012). 
To diagnose over weight and obesity at paediatric age the tools available are: 
Subjects up to 24 months: 
BMI according to the WHO curve, especially if breast fed: overweight can 
be identified for BMI values over 2 SD (standard deviation), also including 
obesity (BMI > +3DS) (Figures 3 and 4).
 
 
FIGURE 3. BMI according to the WHO curve for the girls up to 24 months
 
 
 
FIGURE 4. BMI according to the WHO curve for the boys up to 24 months
 
 
 
 
 
 
Additional information can be retrieved by referring to the weight/length 
relationship according to the reference table published in 2000 by the Center 
for Disease Control and prevention (CDC) in Atlanta (Center for Disease 
Control and Prevention [CDC], 2000) (Ogden CL et al., 2002). Cut-off value: 
85th percentile for overweight and 95th percentile for obesity (Figures 5 and 
6). 
 
 
 
 
FIGURE 5. Weight/length curve, girls, 2000 CDC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6. Weight/length curve, boys, 2000 CDC
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects older than 24 months: 
BMI according to Cole: BMI values for different ages are related 25-29 
values and equal or above 30 for adults, which are the known limits for 
overweight and obesity respectively. The charts were devised by processing 
the anthropometric data collected from the studies carried out in six different 
nations (Table 1).
 
 
 
 
TABLE 1. BMI values for different ages in according to Cole
 
 
 
  Overweight
B.M.I. 25 kg/m2 
Obesity
B.M.I.  30 kg/m2 
Ages Boys Girls Boys Girls 
2 18.41 18.02 20.09 19.81 
2.5 18.13 17.76 19.80 19.55 
3 17.89 17.56 19.57 19.36 
3.5 17.69 17.40 19.39 19.23 
4 17.55 17.28 19.29 19.15 
4.5 17.47 17.19 19.26 19.12 
5 17.42 17.15 19.30 19.17 
5.5 17.45 17.20 19.47 19.34 
6 17.55 17.34 19.78 19.65 
6.5 17.71 17.53 20.23 20.08 
7 17.92 17.75 20.63 20.51 
7.5 18.16 18.03 21.09 21.01 
8 18.44 18.35 21.60 21.57 
8.5 18.76 18.69 22.17 22.18 
9 19.10 19.07 22.77 22.81 
9.5 19.46 19.45 23.39 23.46 
10 19.84 19.86 24.00 24.11 
10.5 20.20 20.29 24.57 24.77 
11 20.55 20.74 25.10 25.42 
11.5 20.89 21.20 25.58 26.05 
12 21.22 21.68 26.02 26.67 
12.5 21.56 22.14 26.43 27.24 
13 21.91 22.58 26.84 27.76 
13.5 22.27 22.98 27.25 28.20 
14 22.62 23.34 27.63 28.57 
14.5 22.96 23.66 27.98 28.87 
15 23.29 23.94 28.30 29.11 
15.5 23.60 24.17 28.60 29.29 
16 23.90 24.37 28.88 29.43 
16.5 24.19 24.54 29.14 29.56 
17 24.46 24.70 29.41 29.69 
17.5 24.73 24.85 29.70 29.84 
The International Obesity Task Force (IOTF) recommends using the BMI 
charts devised by T. Cole. These charts express BMI variations according to 
age up to a BMI value equal 25 to 29.9 kg/m2 or ≥30 kg/m2 at the age of 18 
 
for overweight or obesity, respectively (Cole TJ & Lobstein T, 2012; Couper 
JJ et al., 2009) (Figures 7 and 8). 
 
 
FIGURE 7. BMI according to the Cole curve, girls 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8. BMI according to the Cole curve, boys
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The calculation of the BMI value is recommended at every clinical check-
up. Moreover in case of overweight and of obesity, to better quantify fat 
mass, body composition can be estimated with anthropometric methods 
(by measuring the arm, the waist, the hips, the skinfolds of the triceps, the 
bicep, and the subscapular and suprailiac areas) or more precise method 
devices such as DEXA’s. The triceps skinfold in particular, can be used to 
diagnose the excess of weight according to the reference chart by Barlow & 
Diets (Barlow SE & Dietz WH, 1998). Cut-Off value: between 85th and 95th 
percentile for overweight and 95th percentile for obesity.
 
 
1.1 References
Barlow SE, Dietz WH, 1998, Obesity Evaluation and Treatment: Expert 
Committee Recommendations. Pediatrics 102;e29.
Center for Disease Control and Prevention. Percentile Date Files 
with LMS Values. Atlanta, USA; 2000. www.cdc.gov/growthcharts/
percentile_data_files.htm
Cole TJ, Lobstein T, 2012, Extended international (IOFT) body mass index 
cut-offs for thinness, overweight and obesity. Pediatic Obesity 7: 284-94.
Couper JJ et al., 2009, Weight gain in early life predicts risk of islet 
autoimmunity in children with a first-degree relative with type 1 diabetes. 
Diabetes Care 32(1):94-99.
Krebs NF, Jacobson MS, 2003, Prevention of pediatric overweight and 
obesity. Pediatrics 112(2):424-430.
Ludwig DS. 2012, Weight loss strategies for adolescents: a 14-year-old 
struggling to lose weight. JAMA 307(5):498-508.
Ogden CL et al., 2002, Centers for Disease Control and Prevention 2000 
growth charts for the United States: improvements to the 1977 National 
Center for Health Statistics version. Pediatrics 109(1):45-60.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. ETHIOPATOGENESIS
 
Weight excess appears when the intake of calories is higher than the daily 
expenditure of energy. The cause for excess body fat is thus connected to 
an excess of food in comparison to energy expenditure. The human body is 
made by a group of tissues whose main components are: water, lean body 
mass represented by muscular mass and adipose tissue, with proportions 
that vary according to age. Each individual’s body composition is closely 
related to daily energy expenditure and it is also influenced by diet. The 
quality of energy that we use every day is divided in 3 components: Basal 
Metabolic Rate (BMR), thermogenesis and physical activity. The latter 
component of energy expenditure can be modified by personal will, as 
opposed to the former factors which are genetically predetermined. 
The Basal Metabolic Rate represents the highest share of daily energy 
expenditure and besides being influenced by age and sex it is also 
determined by lean body mass (thus by muscles) whilst water and adipose 
tissue basically live “without energy-expenditure”. 
An active life style and reducing sedentary occasions are the most effective 
strategies to maintain a correct balance between weight and height. Daily 
physical activity of the aerobic medium kind, allows the development of 
muscular mass which determines high daily energy expenditure. The more 
muscular mass the higher will be the body consumption of energy. This 
proves the importance of adequate physical activity; indeed a few minutes 
(45-60 minutes) of physical activity per day are enough. 
Essential obesity is a chronic disease with a multi-factorial origin whose 
main genetic and environmental components (nutrition, physical activity) 
can mutually influence each other with different modalities, mechanisms and 
percentages. 
 
2.1 Environmental factors related to obesity risks 
Many socio-economic and environmental factor both inside and outside the 
family contribute to food intake and to a sedentary life style. Due to a genetic 
predisposition, such factors were able to trigger the progressive increase of 
average adiposity of child population (Dorosty AR et al., 2000). The relative 
risk for an obese child to grow up to be an obese adult increases with age 
and it is directly proportioned to the overweight. Obese children at pre-school 
age have the 26-41% risk of developing obesity during adulthood; for school 
age children the risk is from 42 to 63%; overall the risk for obese children to 
be obese as adults ranges between 2 to 6.5 times in comparison to children 
who are not obese. The risk percentage rises to 70% for obese teenagers. 
Having one or both parents obese is the most important risk factor for the 
manifestation of obesity in a child. Further environmental risks involved in the 
 
development of obesity include:
Ø geographical region (south>north);
Ø density of population (city>countryside);
Ø socio-economic level which is inversely proportional to obesity 
prevalence. The level of education of the family, the type of working 
activity of the parents and the economic incomes of the family are 
somehow associated to obesity in about 60% of cases;
Ø nutritional condition during pregnancy: foetus malnutrition especially 
in the first two trimesters seems to be associated with the 
subsequent development of obesity and with an increased risk of 
hypertension and of type 2 diabetes, independently from familiarity 
or heredity. The most widely accepted hypothesis states that the 
condition of malnutrition provokes metabolic and physiological 
responses in foetuses which are meant to the help the child survive 
in future situations. However if in the following stages of life, food 
becomes more abundant, the same adaptation responses can lead 
to develop hypertension, cardiovascular pathologies and glucose 
intolerance (risk factor for diabetes). If the condition of malnutrition 
affecting the foetus occurs in the third trimester or immediately after 
birth, obesity and related risk percentages will be much lower;
Ø family life standards and food-related habits: these factors heavily 
influence the nutritional habits of the child (Wardle J & Cooke 
L, 2008); sedentary parents who have a high calories intake 
diet will more probably have lazy and obese children. Within the 
family nucleus mothers’ wet-nurse behaviour responding to any 
manifestation of the child by offering food, is considered to be the 
reason why even in the years to follow, the child might use food as a 
way to find comfort (Maffeis C et al., 1998); 
Ø loneliness of children who spend many hours at home in front of the 
TV, videogames and the computer with a subsequent increase of 
sedentary activities and a reduction of energy expenditure (Collison 
KS et al., 2010);
Ø  toxic nutritional environment: easy access to high-energy-dense 
food, at low cost, heavily advertised and with a good taste (Veldhuis 
L et al., 2012). 
 
 
2.2 Anthropometric factors related to obesity risks
• Different ponderal increase for breastfed and infant formula fed children
 
The first three-four months of life have been defined as the critical moment, 
indeed a quick and precocious growth seems to expose to an increased 
risk of obesity in the following stages of life. This has led to think that the 
permanent structuring of the individual’s physiology occurs during the first 
weeks of life and that in this phase lay the foundations of future chronic 
pathologies. Therefore acting on growth during the first year of life could be a 
key strategy to prevent obesity and metabolic syndrome in adulthood. 
Nutrition plays a fundamental role in controlling the speed of growth during 
the earliest stages of life. Many studies have associated infant formula 
feeding with a more rapid growth. At the same time, breastfeeding was 
defined a protective factor against obesity and over weight in adulthood 
(Dewey KG, 2003). The anthropometric indexes collected confirm that there 
is a different growth pattern between breast-fed and formula-fed infants. 
More specifically, the breast-fed child grows more rapidly during the first 2-3 
months of life, than between 6 and 12 months he or she will have a lower 
weight and length than formula-fed children (De Onis M et al., 2009). The 
higher ponderal growth level of formula-fed children as opposed to breast-fed 
children could be explained by the different intake of metabolizing substrates, 
specifically of proteins (Koletzko B et al., 2009): in formula-fed infants the 
protein intake for weight unit is 55-80% higher in comparison to breast-fed 
children. Indeed it is important to remember that during breastfeeding the 
concentration of proteins in breast milk is progressively reduced from 1.6 g/dl 
to 0.8-0.9 g/dl providing during the first year of life 7-8% of total daily energy. 
Instead artificial formulas provide between 1.2 to 1.9 g/dl of proteins. 
Moreover nutritional investigations prove that, at weaning or when cow milk 
is introduced in the infant’s diet, the protein intake increases up to 3-5g/Kg, 
even though the protein requirement tends to decrease as months go by, 
(1.887 g/Kg at 12 months). Recently, two systematic reviews restored the 
connection between rapid ponderal growth levels in the first years of life and 
the subsequent development of obesity (Baird J et al., 2005). Rapid ponderal 
increase would then be an early anthropometric marker of obesity 
development during adolescence and adulthood, and thus of the related 
metabolic consequences (type 2 diabetes), with an even greater forecasting 
quality than weight at birth (Socha P et al., 2011; Li R et al., 2012).
 
 
• Adiposity rebound
Another widely studied aspect, connected with the development of obesity 
during childhood is adiposity rebound (Dorosty AR et al., 2000; Reilly JJ 
et al., 2005). By observing the BMI trend in the general paediatric age 
 
population, one should notice that in the first year of life there is a very rapid 
increase of BMI reflecting the remarkable deposition of the fat stored during 
the first months of life. After the age of one, BMI values diminish to then 
stabilize and increase again generally only after the age of 5-6. The age 
when the body reaches the minimum value of BMI before the physiological 
increase is called adiposity rebound and generally it corresponds to the age 
5-6. An increase of BMI values before the age of 5 (early adiposity rebound) 
is recognized as a marker of precocious risk of developing obesity (Figure 9). 
Therefore the anamnesis (of the pregnancy, the family, the nutrition and the 
life style) and the evaluation of statural-ponderal growth and of BMI are the 
means that allow to identify children more at risk of developing obesity before 
that the actual disorder begins (Dorosty AR et al., 2000;  Scaglioni S et al 
2000;  Rolland-Cachera MF et al, 2006).
 
FIGURE 9.  Adiposity rebound
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3. APPROACH TO THE OBESE CHILD AND CLINICAL EVALUATUION
To be able to intervene with an efficient system and to devise the most 
adequate nutritional education program, the Paediatrician needs, starting 
from the first meeting, to gain as much information as possible on the child, 
on the family and on all elements that may have an influence. Furthermore, 
devising an adequate anamnesis and an objective exam is a way to gain 
the patient’s trust and willingness to undertake a new life style. Indeed if the 
latter were not to be understood and recognized in its importance it may be 
perceived as an imposition from the parents and therefore rejected. 
In 2006 the Italian Society of Paediatricians published a consensus of 
prevention, diagnosis and therapy of essential obesity for the child and for 
the teenager, to be used as reference when dealing with an obese child 
(Consensus Società Italiana di Nutrizione Pediatrica SINUPE, 2001; Società 
Italiana di Pediatria, 2006). 
 
3.1 Anamnesis 
In addition to a general complete and detailed anamnesis it is necessary 
to collect information to verify the risk, within the family, for chronic-
degenerative diseases and obesity, environmental and family factors 
exposing to obesity, possible symptoms that may turn into a non essential 
obesity, nutritional factors and life style. 
• Family anamnesis
- Weight and height (BMI) of parents and siblings;
- Familiarity condition concerning chronic-degenerative diseases in 
relatives with first and second degree of kinship
- Ponderal increase during pregnancy;
- Family attitude towards weight:
- Any possible alterations concerning the relationship with food within the 
family;
- Family awareness and expectations concerning body weight. 
• Physiological anamnesis
- Weight at birth;
- Feeding modality during infancy;
- Statural and ponderal growth and BMI curve;
- Psychomotor development and school performance;
- Presence of first pubertal signs;
- Age of menarche and features of menstrual periods.
• Pathologic anamnesis
- Period when overweight appeared and ponderal increase/year; 
 
- Any previous attempts to reduce weight and patient’s expectations 
concerning ponderal decrease;
- Possible presence of food-related behaviour disorders (EDNOS).
• Nutritional Anamnesis
Collecting precise information on eating habits entails a number of difficulties: 
especially in obese subjects it is very difficult to assess the exact calories 
intake, because either consciously or not there is a general underrating of 
food intake and the consumption of food and drinks tends not to be precisely 
communicated. It was proved that nutritional anamnesis, whatever the 
instrument used, may represent an educational way that allows the patient 
and the family to focus the attention on their habits. Furthermore during 
follow-ups it will allow monitoring whether variations have actually taken 
place and thus assess the efficacy of the intervention that will be devised. 
For this purpose Paediatricians can use: the Food Frequency Questionnaire 
(FFQ), the diet journal of 3 or 7 days or the dietary history. 
• Life habits
- Weekly hours of physical activity and sport;
- Interests;
- Hours of sedentary activities (TV, computer, music, studying); 
it has been estimated that 15% of children at pre-schooling 
age spend more than 5 hours per day in front of the TV (Kuhl 
ES et al., 2012).
• Further information
- Relationship with family members;
- Relationship with school friends;
- Reasons to request medical advice;
- Beliefs concerning the topic of obesity;
- Self-evaluation of excess weight;
- Patient’s and family expectations in terms of weight loss;
- Patient and family willingness to change food and life habits. 
 
3.2 Clinical evaluation
The clinical exam of an overweight child or teenager, in the majority of cases 
allows to diagnose an essential obesity (or a primitive one) or at least to 
suspect an endocrinal or genetic cause. 
The child affected by essential obesity has very precise features: 
• Normal psychomotor development
• Obesity developed gradually, with highest incidence for school age 
and adolescence; 
• The distribution of fat is even on the face, the trunk and on limbs;
 
• Average or above average height, with an even growing curve;
• If analyzed, bones maturation will result accelerated and 
corresponding to the statural age; 
• Pubertal maturation is generally accelerated;
• Pseudo-hypogenitalism: the genitals of the obese child usually 
appear to have a reduced size due to the ample presence of fat 
which hides the genitalia, however an accurate exam will reveal that 
they have a normal size;  
• Pseudo-gynecomastia: a condition which usually worries young 
patients as well as their families, when actually is only excessive fat;
• Possible furunculosis and intertrigo in skinfolds as well as stretch 
marks on the skin of the abdomen, hips, sides, thighs, buttocks, 
breasts and at times on the arms and legs. Marks are usually whitish 
or red, mostly caused by mechanical-type factors; 
• In case of severe obesity there is a chance of finding acanthosis 
nigricans, which is a lesion marked out by hyper-pigmented areas of 
skin, with a velvety, verrucose surface localized at the bottom of the 
neck, in the armpit, in the groin and in the folding areas of the limbs. 
This is an important sign of an altered carbohydrates and insulin 
metabolism (Figures 10 and 11). 
 
FIGURE 10. Acanthosis nigricans
 
 
FIGURE 11. Acanthosis nigricans
 
 
 
 
 
 
 
 
• Genu valgum and flat feet are also frequently present in the obese 
child. These are caused by the stress on the joints by the high 
ponderal load. Pain in the hips and in the lower limbs are also 
frequent and they are caused by a coxa vara or by a slipped capital 
femoral epiphysis;
• Normal performance at school;
• Absence of stigmata malformation; 
The full objective general examination is characterized by the collection of the 
following: 
• Height and, when possible, the retracing of the growth curve;
• Weight and the retracing of the ponderal growth curve through the 
evaluation of previous weights, to assess the speed of ponderal 
increase;
• Estimate of the ideal weight in relation to height and to the 
measurement of the overweight percentage;
• measurement of BMI;
• body circumferences (arm, waist, hips). Body circumferences reveal 
the cross-sectional sizes of the body segments and indicate the 
current nutritional condition and the distribution of body fat as well as 
 
growth. 
The most paediatric relevant circumferences to assess the nutritional 
condition of the child are three: circumference of the waist, the hips 
and the arm. At paediatric age, waist circumference alone can be 
considered a marker of cardiovascular risk in overweight subjects. 
McCarthy report cut-off values (90th percentile) referring to minimum 
waist circumference (collected with the procedure indicated by OMS 
(McCarthy HD et al., 2001).
Furthermore it was recently suggested that a ratio waist 
circumference (cm)/height (cm) >0.5 is associated to a higher risk to 
develop cardiovascular pathologies, therefore during diagnosis the 
said ratio should be carefully assessed (Mokha JS et al., 2010). 
The ratio between waist and hips circumferences (WHR, waist hip 
ratio) is instead an anthropometric index that can be used to evaluate 
the distribution of body fat. More specifically, abdominal or “android” 
fat distribution, indicated by WHR values higher than 1 for men and 
higher than 0.8 for women, is considered to expose to a higher risk. 
The most appropriate techniques to study visceral fat in a paediatric 
context are: DEXA, bioelectrical impedance analysis, nuclear 
magnetic resonance (NMR) and computerized tomography. Due to 
costs and/or invasiveness such methods should be restricted to a 
limited number of patients. 
• Skinfolds (triceps, bicep, subscapular, suprailiac).
Skinfolds testing is the most widely used method to measure body 
fat. By measuring subcutaneous fat, with the calliper, it is possible to 
estimate, using appropriate equations, the overall content of body fat, 
assuming that subcutaneous fat represents a constant fraction of the 
total. Skinfolds can be measured in a number of areas of the body, 
however the most frequently tested ones are the biceps, the triceps, 
the subscapular and the suprailiac. The triceps skinfold can be used 
as an additional method to diagnose ponderal excess and to monitor 
diet therapy for obesity and for slimness. The said skinfold is closely 
linked to both total and percentage body fat, but it is less correlated 
to blood pressure. The biceps skinfold, combined with the triceps 
skinfold, can be useful to estimate total body fat. The subscapular 
skinfold is an important index of the nutritional condition and it is also 
useful to measure the total mass of body fat. The suprailiac skinfold 
is an index of body fat and its assessment is important in relation to 
the risk of metabolic syndromes. 
• Pubertal stage; 
 
• Size of the thyroid gland and search for possible hyperthyroidism 
symptoms; 
• Blood pressure. In overweight subjects, who are more at risk to 
develop hypertensions, blood pressure should always be measured 
by using appropriate bracelets (the bracelet should be placed =40% 
arm circumference) for each child. 
The American Academy of Pediatrics (AAP) indicated hypertension 
reference values according to sex, age and height. To be defined as 
“Normal blood pressure” values should be lower than 90th percentile, 
“hypertension condition” if values are between 90th and 95th 
percentile, “arterial hypertension” if values are above 95th percentile; 
• Presence of possible gynecomastia; 
• Possible presence of stretch marks or acanthosis nigricans;
• Orthopaedic alterations
 
3.3 Laboratory and instrumental investigations
Laboratory investigations shall be pursued in relation to the level of obesity 
and to the familiarity with cardiovascular risk factors (diabetes mellitus, 
hypertension, dyslipidemia, cardiovascular diseases). Moreover, tests 
should try to identify in advance, possible markers of a secondary metabolic 
syndrome in the overweight condition of the child. Screening must include: 
• Fasting blood glucose (reference value < 100 mg/dl or 5.6 mmol/
l; fasting glucose intolerance: 100-125 mg/dl or 5.6-6.9 mmol/
l; diabetes: ≥ 126 mg/dl or 7 mmol/l). For fasting blood glucose 
>100mg/dl which is often confirmed, there is a curve indicating the 
oral intake of glucose (0-120 minutes). Blood sugar values between 
140 and 200 mg/dl after 120 minutes from glucose administration, 
tends to indicate a glucose intolerance, whilst a value above 200 mg/
dl clearly indicates a diabetes mellitus type 2;
• Fasting insulinaemia: according to Consensus guidelines for 
prevention, diagnosis and therapy of obesity in the child and in 
the adolescent, basal insulin values above 15 (> 15 μU/ml) should 
be compatible with insulin resistance regardless of sex and age. 
However the Consensus publication on insulin-resistance at 
paediatric age states that basal insulin dosage alone is not sufficient. 
In 2009 the Italian Society of Paediatric Endocrinology and Diabetes 
(ISPED) set the normality cut-offs for insulin sensitivity, insulin 
secretion by pancreas β-cells and insulin-resistance according to sex 
and pubertal stages based on a population of healthy Italian children 
and teenagers using index such as: QUICKI Index (Quantitative 
 
Insulin-Sensitivity Check Index), HOMA-β% (HOMA of percent of β-
cell function) HOMA-IR (Homeostasis Model Assessment of Insulin-
Resistance Index) (Katz A et al., 2000; D'Annunzio G et al., 2009). 
 
                    [fasting insulinaemia (μU/l) x basal blood sugar (mmol/l)] 
 HOMA-IR=                                            
                                                            22.5
 
                                                     1
QUICKI =        
                  (log10 basal insulin in mU/I + log10 blood sugar in mg/dl)
 
                        (20 x basal insulin in mU/I)
HOMA-β% =                      
                           (blood sugar in mmol/l-3.5)
 
• lipid profile: triglycerides (standard values: <95th percentile according 
to age and sex), total cholesterol (reference value < 180 mg/dl), HDL 
cholesterol (reference value > 40 mg/dl), LDL cholesterol (reference 
value < 130 mg/dl);
• transaminases: ALT (reference value < 40 UI/L), AST (reference 
value < 35) . In case hepatomegaly and/or hypertransaminasemia 
are detected close examinations of liver function and liver ultrasound 
should be carried out;
 
3.4 Evaluation of the risk for related cardiovascular diseases 
• Obesity is a cardiovascular risk factor
• Waist circumference alone can be considered a marker for 
cardiovascular risks in overweight subjects. 
• Hypertension: is defined: 1) “normal blood pressure” if values are 
below 90th percentile; 2) “hypertension condition” if values range between 
90th and 95th percentile; 3) “arterial hypertension” if values are above 95th 
percentile.
An in-depth diagnostic examination should be carried out in overweight 
patients showing hypertension based on:
o Cardiologic medical examination – ECG – echocardiography
o Evaluation of the possibly related Metabolic Syndrome 
o Blood creatinine and kalaemia 
o Standard urine test 
o Microalbuminuria 
 
 
3.5 Evaluation of the risk for related endocrine-metabolic diseases
In an obese child it is important to carry out a screening for the diagnosis 
of metabolic Syndromes even though so far there is no shared criterion for 
paediatric age or for adult age (NCEP ATP III). The International Diabetes 
Federation (IDF) recently published the first Consensus on the definition of 
metabolic syndrome which divides the paediatric population in three ranges 
(Table 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2. The IDF consensus definition of metabolic syndrome in children 
and Adolescents
 
 
Age group
(years)
Obesity*
(WC)
Triglycerides HDL-C Blood
pressur
e
Glucose
(mmol/L) or
known T2DM
 
6–<10 ≥90 th
percentile
Metabolic syndrome cannot be diagnosed, but further 
measurements should be made if there is a family history 
of metabolic syndrome, T2DM, dyslipidemia, cardiovascular 
disease, hypertension and/or obesity.
10–<16
Metabolic 
syndrome
≥90th
percentile or 
adult cut-off if 
lower
≥1.7mmol/L 
(≥150 mg/dL)
<1.03mmol/L 
(<40 mg/dL)
Systolic 
≥130/
diastolic 
≥85 
mm Hg
≥5.6 mmol/L 
(100 mg/dL) 
 
(If ≥5.6 
mmol/L [or 
known T2DM] 
recommend 
an OGTT)
16+
Metabolic 
syndrome
Use existing IDF criteria for adults, i.e:
Central obesity (defined as waist circumference ≥ 94cm for Europid men and 
≥ 80cm for Europid women, with ethnicity specific values for other groups*)
plus any two of the following four factors:  
• raised triglycerides: ≥ 1.7mmol/L 
• reduced HDL-cholesterol: <1.03mmol/L (<40 mg/dL) in boys and 
<1.29mmol/L 
(<50 mg/dL) in girls , or specific treatment for these lipid abnormalities 
• raised blood pressure: systolic BP ≥130 or diastolic BP ≥85mm Hg, or 
treatment of previously diagnosed hypertension
• impaired fasting glycemia (IFG): fasting plasma glucose (FPG) ≥5.6 mmol/
L
 (≥100 mg/dL), or previously diagnosed type 2 diabetes
 
WC: waist circumference; HDL-C: high-density lipoprotein cholesterol; T2DM: 
type 2 diabetes mellitus; OGTT: oral glucose tolerance test. 
*The IDF Consensus group recognises that there are ethnic, gender and age 
differences but research is still needed on outcomes to establish risk.
 
 
3.6 Evaluation of the risk for related gastroenterological diseases
In an obese child the risk for steatosis should always be taken into 
consideration. In children with ALT values confirmed above 40 U/L it is 
advised to carry out a closer diagnostic examination based on: 
o Blood gamma glutamyltransferase
o Liver ultrasonography
o Hepatitis differential diagnosis 
 
3.7 Evaluation of the risk for related respiratory and otorhinolaryngology 
diseases
In presence of respiratory symptoms such as bronchospasm, snoring at night 
and sleep apnoea, the patients should undergo the following: 
o otorhinolaryngoiatric evaluation
o Respiratory function examination (spirometry)
o Possible polysomnographic examination. 
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4. TYPICAL FEATURES OF AN OBESE CHILD DIET 
Diet has definitely a key role in the development of essential obesity. Indeed 
it is important to bear in mind that even children and teenagers with normal 
weight make daily nutritional mistakes. Besides the most common mistakes 
of the whole paediatric population, obese subjects present additional 
erroneous nutritional behaviours that further jeopardize the difficult balance 
between calories intake and energy expenditure. More specifically, the diet 
features of the obese child are partially related to those committed by the 
vast majority of the paediatric population in general, as well as being peculiar 
to this category of patients. 
The main diet mistakes in an obese patient are:
o Excessive food intake in comparison to caloric expenditure 
(a very sedentary lifestyle)
o Skipping breakfast intake
o Obese children who do have breakfast, do however tend to 
eat very little in the morning
o Tendency to eat preferably in the afternoon and in the 
evening, and often outside main meals; tendency to eat a lot 
of snacks in the afternoon and in the evening. 
o Scarce intake of whole grains, pulses, fish, fibre, seasonal 
vegetables and fruit. 
o High intake of sugars with high glucose index (potatoes, 
bread, pastries, refined grains) cold cuts, cheese and meat
o Predilection for liquid foods (i.e. fruit juice) or particularly 
creamy ones that do not require chewing (i.e. cakes, 
puddings, muffins).
 
 
5. OBESITY COMPLICATIONS
At the same age, mortality is generally higher in obese adults than in non-
obese ones. For the obese child there is no actual risk of death. However, 
considering the high persistency (30-60%) of paediatric obesity during 
adulthood, it is reasonable to think that precocious metabolic modifications 
are related to morbidity and mortality in the medium to long term. Mortality 
during adulthood is mainly caused by cardiovascular diseases, and the main 
factors for this are arterial hypertension, arteriosclerosis, dysplidemia and 
diabetes mellitus (Park MH et al., 2012).
All the aforementioned metabolic alterations are generally associated 
with obesity and usually, at paediatric age, they do regress by improving 
the condition of overweight and of obesity. Many of the metabolic and 
cardiovascular complications (insulin-resistance, diabetes mellitus type 
2, metabolic syndrome, hypertension) that until a few years ago were 
considered as peculiar problems of adulthood, have now become relevant 
pathologies for paediatric age too. For this reason the later consequences 
of paediatric obesity include both the persistency during adulthood of 
the obesity and morbidity originated during childhood and cardiovascular 
disorders. The latter are especially arteriosclerotic based ones, such as 
an increased risk for gout and for a number of tumours (colorectal) for the 
man and for arthritis and menstrual disorders for the woman, as well as an 
increase of cardiovascular mortality due to general causes. 
                            
5.1 Insulin-resistance
Insulin-resistance is a risk factor for many pathologies, among which diabetes 
mellitus type 2 is the predominant one. In the child as well as in the adult it 
is determined by the combination of insulin-resistance with an insufficient 
secretion from beta cells. Obesity is one of the main causes for altered insulin 
sensitivity and thus for insulin-resistance; indeed the majority of patients 
suffering from diabetes mellitus type 2 are obese. 
Ethnical and geographical differences in the incidence of insulin-resistance 
indicate that this alteration is an extremely complex metabolic disorder, 
with a heterogeneous aetiology. The disorder is indeed determined 
by environmental and social risks that unmask individual underlying 
susceptibility. 
The role plaid by genetic factors is evident when considering the prevalence 
differences of such disorders among different ethnic groups. The Afro-
American population in particular, resulted as the most insulin-resistant one 
(Arslanian S, 2002). Environmental factors which were proved to be involved 
in the development of insulin-resistance include, besides the aforementioned 
 
obesity, a positive energetic balance, a sedentary lifestyle, a diet with a lot of 
high glucose index food, high in fat and high in proteins. 
Insulin-resistance is a condition characterized by the inability of insulin to 
adequately stimulate the access of glucose inside cells. It is determined by 
a number of causes, but whichever the origin may be, the consequence 
is a diminished use of glucose, that accumulates in the circulation and 
further stimulates insulin secretion. At the first stage, the hyperinsulnaemia 
created fosters the cellular collection of glucose, which initially is able to 
overcome insulin-resistance and to maintain euglycemia. At a second stage, 
glycemic levels become progressively higher with a further increase of insulin 
secretion: at this stage glucose intolerance is manifested. Postprandial 
glucose values appear high (> 126 mg/dl) and they do not allow an adequate 
pancreatic response, but on the contrary they reduce it and cause the onset 
of diabetes mellitus type 2.
The circulation of free fatty acids plays a key role in determining the alteration 
of carbohydrate metabolism in the obese subject. High adipose mass causes 
a greater turnover of fats due to an increased hydrolysis and a higher re-
esterification of triglycerides. The Free Fatty Acids (FFAs) , being more 
available are oxidized at liver and muscle level causing an increase of cellular 
production of Acetyl-Coa that stimulates gluconeogenesis at hepatic level 
and inhibits the oxidation of glucose at muscular level. The lower peripheral 
use of glucose causes a receptors down-regulation, with a reduction of the 
number and of the activity of insulin receptors and a lower turnover of liver 
glycogen. Furthermore the high concentrations of FFAs are able to interfere 
with the binding between insulin and its receptor and in some of the post-
receptor processes with the transduction of the signal. 
In the last decade, the adipose system has been considered as a proper 
endocrine tissue, secreting hormonal substances, “fat hormones”, which 
were recently renamed “adipocytokines”, which mainly function to regulate 
energy homeostasis. Recent scientific evidences prove that adypokines can 
play an important role for the genesis of obesity and of related pathologies. 
Among all these hormonal substances, adiponectin is one of the most studied 
adipocytokines of the recent years. Normal size adypocites physiologically 
secrete “insulin sensitive” hormones including adiponectin. However, in 
situations of adipocyte hypertrophy caused by hyper-caloric diets, there is 
a decrease of production and secretion of “insulin-sensitizing” hormones, 
and an increase in “insulin-resistant ones”, with the result of fostering a 
condition of increased adiposity and of insulin-resistance. Adiponectin acts by 
reducing lipid synthesis and glucose production by the liver, causing a drop of 
blood free fatty acids and of glucose synthesized through gluconeogenesis. 
 
Therefore the production of triglycerides by the liver also results reduced. 
In fact adiponectin also acts by increasing the oxidation of fats by muscular 
tissue and thus the consumption of energy, probably by regulating the 
synthesis and the activity of proteins related to triglycerides metabolism (CD 
36, Acetyl-Coa oxidase, PPARα).
Insulin-resistance is responsible for the increased risk of cardiovascular 
pathologies through a number of mechanisms: 
• loss of the endothelial protecting effects of insulin such 
as vasodilatation, reduction of the antioxidant condition, 
anti-inflammatory action, antithrombotic, profibrinolytic, 
antiatherosclerotic; 
• inhibition of lipid metabolism and thus induction of dyslipidemia that 
contributes to the induction of endothelial malfunction;
• stimulation of the sympathetic nervous system with increased levels 
of norepinephrine, a vasoconstrictor agent inducing higher blood 
pressure;
• sodium retention action of insulin. 
The above data account for the use of the intima-media thickness (IMT) 
measure of the carotid artery as a precocious marker of cardiovascular risk. 
 
5.2 Fatty Liver Disease (FLD)
Fatty Liver Disease (FLD) represents one of the earliest complications linked 
to obesity and insulin-resistance, and it is the most frequent cause for chronic 
hepatopathy at paediatric age. The term NAFLD (Non Alcoholic Fatty Liver 
Disease) describes a wide range of clinical-pathological entities, starting from 
simple fatty liver moving to non-alcoholic steatohepatitis, up to cirrhosis and 
terminal stage hepatic disease. 
An autopsy study carried out in the United States on children who died for 
accidental causes, indicated that 9.6% of the American population between 
the age of 2 and 19 presents NAFLD and the value tends to increase up to 
38% for obsess children (Schwimmer JB et al., 2006). Steatohepatitis defines 
the accumulation of lipids inside the hepatocyte, considered pathological only 
when values are above 5% of the liver’s weight. Lipid accumulation generally 
includes triglycerides, more rarely sphingolipids or cholesterol esters. There 
are two fundamental histological variations of fatty liver: macrovescicular 
steatosis whereby a voluminous lipid vacuole displaces the nucleus laterally, 
o microvescicular steatosis whereby the central nucleus of hepatocyte is 
surrounded by lipid drops.  
Macrovescicular steatosis (the most frequent histological type) is generally 
caused by a number of alterations of the lipid metabolism, of toxic, 
 
dysmetabolic, nutritional or hereditary nature. This type of steatosis is 
frequently found in cases of chronic alcoholism, obesity, insulin-resistance, 
diabetes, cachexia, drug-related hepatopathy, hereditary metabolic disorders, 
HCV and CMV hepatitis, autoimmune hepatitis, Wilson’s disease and in 
cystic fibrosis.
The pathogenesis of macrovescicular steatosis is caused by the shift of 
lipolysis towards lipogensis, with a subsequent intrahepatic accumulation of 
lipids. 
Microvescicular steatosis is found instead in conditions of acute alterations 
of mitochondrial and ribosomal functions. FFA transported to the liver 
derive from the plasma hydrolysis of chylomicrons after a meal or from 
the triglycerides of fatty tissue during fasting. Inside the liver acid fats can 
be oxidized in the mitochondria (β-oxidation) or they can be used for the 
synthesis of triglycerides, phospholipids or cholesterol esters. 
An increase of FFA uptake at hepatic level can be secondary to:
- an increase of lipids or carbohydrates in the diet
- an increase of circulating FFA levels (obesity, dyslipidemia)
- greater mobilization of triglycerides in presence of a reduced 
sensitivity of tissue receptors to insulin actions (insulin-
resistance)
At paediatric age the prevalence of NAFLD increases at the same time of the 
diffusion of obesity, therefore it was essential to retrieve diagnostic standards 
that could be used by paediatricians and hepatologists. 
The diagnostic gold standard of NAFLD is histological examination. The 
said method is not a suitable screening procedure due to its invasiveness 
and for the excessive costs, therefore it was necessary for research to find 
hepatopathy markers. Currently, to assess the level of fibrosis and steatosis 
as well as the risk for the progression to terminal a stage of hepatopathy 
further methods are being used: imaging through hepatic ultrasound and/or 
magnetic resonance, serum markers for function and hepatic fibrosis. 
Despite some of the aforementioned markers are generally used for the 
diagnostic appraisal of a patient suspected of NAFLD, none of these seem 
to have the high specificity and sensitivity required to certainly rule out other 
underlying hepatic diseases. 
In clinical practice the diagnosis of NAFLD is generally suggested by results 
showing hepatobiliary enzymes (especially ALT and GGT) above the normal 
range and/or by positivity to the ultrasound evaluation. In overweight patients 
above the age of 3, with high waist circumference and NAFLD positive 
familiarity, the first diagnostic examination should consist of abdominal 
ultrasonography, the evaluation of hepatic function markers together 
 
with anamnesis and clinical data, to exclude other possible causes for 
hepatopathy. 
A NAFLD activity score (NAS) (Brunt EM et al., 2009) was suggested in the 
attempt to standardize the diagnostic histological criteria for NAFLD. 
The score is based on the weighted sum for each of the following lesions: 
• steatosis (0-3)
• lobular inflammation (0-3)
• ballooning de generation of hepatocytes (0-2).
A score > 5 strongly suggests the presence of NASH (Non Alcoholic 
Steatohepatitis), whereas a score < 3 strongly indicates the absence of 
NASH. 
However the histological features of NASH at paediatric age are different 
to those retrieved in adults. In a study conducted by Schwimmer et al 
(Schwimmer JB et al., 2005) 100 obese or overweight children underwent 
hepatic biopsies. 
Three distinct pathological types were derived from the results hereby 
obtained:
TYPE 1: presents the same features found in the adult (ballooning 
degeneration, lobular inflammation, with/without perisinusoidal fibrosis and 
without portal inflammation (17%); 
TYPE 2: predominant one (51% of the survey), is distinguished by the 
presence of macrovescicular steatosis with portal inflammation, with/without 
portal inflammation in absence of ballooning degeneration and perisinusoidal 
fibrosis;
TYPE 3: overlapping of the other two types.  
According to recent indications, hepatic biopsy is recommended: 
- to rule out any other curable diseases,
- in case of clinical suspect for a hepatic disease at advanced stage, 
- before starting a pharmacological/surgical treatment, 
- as part of the protocol or a research trial.
Considering the limitations of the said procedure, there has been a thorough 
study of alternative methods that could replace biopsy evaluation for the 
diagnosis and the monitoring of NAFLD. 
The most significant include: 
• Hepatic ultrasound: it is the most commonly used imaging method for 
the screening of NAFLD, as it is safe, widely available and scarcely 
expensive. In case of steatosis the liver appears hyperechogenic. 
The level of lipid infiltration is assessed on the basis of the extent of 
echogenicity. This technique presents sensitivity values ranging from 
60 to 96% and a specificity between 84 and 100%. 
 
• CAT (computed axial tomography) without contrast agent: presents 
sensitivity and specificity values similar to those of the ultrasound. 
However it exposes the patient to radiations, reason why this 
technique is not frequently used, especially at paediatric age. 
• Magnetic Resonance Imaging (MRI): it is able to measure in a 
reliable way the fat infiltration in the liver. This technique, is growingly 
receiving more interest especially at paediatric age as it is not 
invasive and it does not expose to radiations. 
An emerging imaging modality for the quantitative evaluation of 
hepatic steatosis is spectroscopy 1H-MR (1H-MRS). The diagnostic 
sensitivity and precision of such procedure varies between 87 and 
100% and between 80 and 85% respectively. 
 
5.3 Metabolic Syndrome
Metabolic Syndrome (MS) was defined for the first time by Reaven et al as a 
combination of cardiovascular risk factors such as obesity, insulin-resistance, 
glucose intolerance or diabetes mellitus type 2 (DMT2), arterial hypertension 
and dyslipidemia (intended as high density levels of lipoproteins, HDL 
reduced and high triglycerides values). If in adults MS is difficult to define it is 
even more complicated to do so in a paediatric context. 
Recently (2007) the International Diabetes Federation suggested a 
new definition of MS for developmental age with the aim of making its 
identification easier and more practical, so to improve in speed and precision 
the detection of the syndrome in children and adolescents at risk of 
developing DMT2 (Table 2) (Zimmet P et al., 2007). 
As far as dyslipidemia is concerned, it is known that the obese subject 
presents higher circulating levels of FFAs in comparison to a normal weight 
one, due to the inability of the insulin to inhibit their release in the circulations. 
Triglycerides are also higher for the greater availability of precursors at 
hepatic level (FFAs and glucose), with an increase in the production of VLDL 
(very low density lipoprotein) and a lower removal from the bloodstream 
due to the reduced activity of lipoprotein lipase. Therefore there is a high 
concentration of VLDL causing an increase of LDL synthesis. The lower 
activity of lipoprotein lipase also diminishes the synthesis of HDL. In the 
obese child total average cholesterol levels and triglycerides are not 
constantly higher than those of the non-obese child, whereas the HDL/LDL 
ratio is generally inferior, same as for adults. 
Hypertension (blood pressure values above 95th percentile according to 
sex and age) is not frequent in the child with ponderal excess, even though 
average blood pressure values in the obese are significantly higher than 
 
those of the control-population. High blood pressure values are matched with 
the level of adiposity and with the duration of the obesity. The mechanism 
whereby insulin contributes to the increase of systolic pressure values is 
triggered by its sodium-retentive effect.  
All the metabolic complications of child obesity are reversible, completely or 
partially, with the loss of weight. Even a moderate loss of weight can bring 
significant metabolic improvement. 
 
5.4 Hormonal modifications
In the obese subject the circadian rhythm of cortisol is preserved, 
however there can be evidences of high secretion levels of cortisol and of 
corticosterone metabolites. The increased clearance of cortisol provokes 
a stimulation of ACTH secretion, which causes an increase of andrenal 
androgens (dehydroepiandrosterone sulphate and testosterone), attested by 
increased levels of urinary 17-ketosteroids causing precocious adrenarche in 
these children. 
The secretory response of the growth hormone (GH) both spontaneously and 
in relation to exercise, sleep, hypoglycaemia, arginine and to GHRH will be 
reduced in the obese child in comparison to normal weight control groups. 
On the contrary the insulin-like growth factor (IGF-1) is usually higher in the 
obese. Such modifications are reversible with a reduction of the adipose 
mass. Despite the reduced levels of GH, the child with essential obesity does 
not show growth deficit, actually during the pre-pubertal period or during the 
early pubertal one he or she will have height above the norm. Moderately 
high triiodothyronine values (T3), even within norm limits are frequent in 
obese children and adults alike. This is determined by a greater peripheral 
conversion of T4 (thyroxine or tetraiodothyronine) in T3. 
Gonadal activity in the obese child is essentially normal. Adrenarche 
is usually early, but sexual development is regular. In the female, early 
menarche is common, often followed by alteration of the menstrual cycle 
such as amenorrhea, dysmenorrhoea and dysfunctional uterine bleeding. 
The Polycystic ovary syndrome is relatively frequent, characterized by 
the presence of many (>10) ovary cists with a diameter of more than 4cm 
associated with amenorrhea, dysfunctional uterine bleeding, signs of 
hyperandrogenism (hirsutism, virilization). Such syndrome is frequently 
associated to hyperinsulinemia. 
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6. OBESITY TREATMENT
Treating essential obesity at developmental age should tend to positively 
and persistently affect the child’s diet, behaviour and physical activity thus 
therapeutic programs should intervene on all three levels (Kaneita Y et al., 
2008). 
As far as essential obesity dietary therapy is concerned, its main goals can 
be summarized as follows: 
•Reducing overweight and finding a new balance between energy 
expenditure and caloric intake (by improving physical activity and by 
persistently modifying life style and nutritional habits), not reaching 
ideal weight; 
• conservation of lean body mass, especially muscular mass which represents 
the metabolically active compartment of the body, which is able to 
positively affect basal metabolism, and consequently the energy 
expenditure; 
• reducing lean body mass;
• maintaining adequate growth rhythms;
• achieving a correct weight-stature ratio;
•appropriate nutrition with an adequate repartition of nutrients as well as 
choosing food that induces a high sense of satiety; 
• preserving the statural-ponderal balance achieved;
• preventing obesity-related complications. 
When intervening on childhood obesity the aim is to regulate body weight 
and fat mass by acting adequately from an anthropometric as well as a 
psychological standpoint. To achieve a correct and lasting ratio between 
weight and height, the therapeutic program should be able to radically 
modify nutritional and life habits of the child and of the family with a proper 
educational action. Thus the involvement and collaboration of the whole 
family are essential conditions for the success of the therapy devised. 
Nutritional education is the cornerstone of dietary treatment for childhood 
essential obesity. 
 
6.1 Diet
A balanced and normocaloric diet, matched with an improvement of physical 
activity aiming to obtain a reduction of overweight through safeguarding 
weight is an appropriate treatment for:
ü Children below 8 years of age
ü Children above 8 years of age old with: mild or moderate 
ponderal excess (on the basis of BMI evaluation) without any 
further complications or clearly hypercaloric nutritional habits
Normocaloric diet is based on the following principles: 
 
• CALORIC INTAKE corresponding to the one indicated by RDI 
according to sex and statural age, divided in 4-5 meals with the 
following repartition of calories: breakfast + snack 20%, lunch 40%, 
snack 10%, dinner 30%.
• PROTEIN INTAKE: 10-12% of the energy intake (1:1 ratio between 
animal and vegetable proteins)
• CARBOHYDRATE INTAKE: 60-65% of the energy intake (with an 
amount of high-glucose-index sugars < 10% of total calories)
• LIPIDS INTAKE: no restriction up to the age of 2 years old. After the 
age of 2 progressive reduction from 30 to 25% of total calories with a 
saturated fat intake  < 10% of the energy intake and cholesterol not 
exceeding 100 mg/1000 kcal
• FIBER INTAKE: the amount of grams can be calculated on the basis 
of the following formulas: between age +5 and age +10 or equal to 
10 g/1000 kcal, or even equal to 0.5 g/kg of ideal weight
• MINERAL INTAKE as indicated by Recommended Dietary Intakes 
(RDI) guidelines.
 
The advised repartition of protein sources with a high biological value as well 
as of main nutrients is as follows: 
• More times per day CEREALS: pasta, rice, barley or spelt for both 
lunch and dinner. Preferably wholemeal bread or type 1 flour for 
breakfast, lunch and dinner, being careful to avoid excesses
• At least 2 times per day VEGETABLES AND FRUIT
• 4 times per week FISH
• 4 times per week LEGUMES
• Not more than 3-4 times per week MEAT
• 1 time per week CHEESE
• 1 time per week EGGS
If the family collaborates, this type of approach is characterized by a good 
acceptation of variations, especially qualitative ones, without excessive 
restrictions and thus it allows a gradual and lasting reduction of overweight 
and the acquisition by the child and by the family of a correct nutritional 
education. Awareness of the nutritional habits of the overweight-obese child 
allows targeting nutritional interventions (Ferrie JE, et al., 2011; Wisor JP et 
al., 2011). 
 
6.2 References
Ferrie JE et al., 2011,  Change in sleep duration and cognitive function: 
findings from the Whitehall II study. Sleep 34 (5): 565-573.
 
 
Kaneita Y et al., 2008, Associations of usual sleep duration with serum lipid 
and lipoprotein levels. Sleep 31(5):645-52.
 
Wisor JP et al., 2011, Evidence for neuroinflammatory and microglial 
changes in the cerebral response to sleep loss. Sleep 34 (3): 261-272.
 
 
 
7. FATTY ACIDS
 
7.1 Description 
Fatty Acids are constituted by an alkyl chain with a carboxylic group at the 
end. The general formula is R-COOH, where the R group is represented by a 
linear chain shaped CH3 (CH2)n. The latter chain can have variable lengths 
between 2 and 30 atoms of carbon, however the most widespread and 
important fatty acids have between 12 and 22 atoms of carbon. Depending 
on the number of carbon atoms, fatty acids are distinguished for practical 
reasons between short chain fats (1-6 C), medium chain fats (8-12 C), long 
chain fats (14-20 C) and very long chain fats (> 22 C). Furthermore fatty 
acids are also grouped together according to the presence of double or treble 
bonds in two categories: SAURATED and UNSATURATED. 
Saturated fatty acids, such as myristic acid (14:0), palmitic acid (16:0) and 
stearic acid (18:0) have simple chemical bonds and result more stable to heat 
and oxidation. These acids are contained in animal fats, such as butter, lard 
and meat.
Unsaturated fatty acids can contain one (monounsaturated) or more 
(polyunsaturated) “double or treble” bonds. They are more easily digested 
and absorbed than saturated ones, but they are more susceptible to 
oxidation. These are found in vegetable food (olive and seeds oil, hazelnuts 
and peanuts). The most important monounsaturated fatty acid is oleic acid 
(18:1 n-9), which is present in large quantities in olive oil. Double bonds make 
the structure of fatty more fickle; for this reason, cellular membranes with 
high unsaturation index present greater fluidity which is an essential condition 
especially for nervous structure, whereby more fluid membranes guarantee a 
quicker transmission of the nerve signal. 
Unsaturated fatty acids are also grouped together in families according to 
the distance, in terms of atoms of carbon, of the first bond from the methyl 
end. Families range between n-1 and n-12, however the most important 
ones group together n-3, n-6 and n-9 fats. Fatty acids within each family 
are biosynthetically related, being interconvert by enzymatic processes of 
desaturation and elongation of the chain. The enzymes involved in these 
metabolic processes are however common to all three series, and for this 
reason, the essential fatty acids of the different families compete among 
themselves for the synthesis of long chain compounds when these are not 
adequately provided by the diet (Figure 12). 
 
 
FIGURE 12. Metabolic transformation of essential fatty acids in LCPUFA
 
 
 
 
 
Among essential acids there is linoleic acid (18:2 n-6, LA), a very widespread 
fatty acids from the n-6 family. As this acid cannot be synthesized by the 
body, it has to be introduced through the diet. It can be found virtually in all 
vegetable, in greater quantities in seeds, nuts, grains and pulses. It is also 
available in lower quantities in animal fats and in fish oil. 
Another essential fatty acid is α-linoleic acid (18:3 n-3, LNA) which belongs 
to the n-3 family. Like linoleic acid, this one too is available in significant 
quantities in the vegetable realm. It is found in green leaves, including 
phytoplankton and algae, in some seeds, nuts and pulses. 
Essential fatty acids are vital to maintain the functioning and the integrity of 
cellular membranes. Furthermore these acids participate, with a regulating 
function, to metabolism and fats transportation and to the biosynthesis of 
prostaglandins, which are chemical substances regulating many bodily 
functions, including blood pressure and immune and inflammatory responses. 
 
For biological purposes, derivates from the n-3 series (Cottin SC et al., 2011; 
Origin Trial Investigators, et al., 2012) have particular importance as they 
determine: 
• Improvement for the metabolism of lipids and of lipoproteins 
(reduction of cholesterol and of triglycerides); 
• Effects on blood pressure and on cardiac functions (antyarrhythmic 
effect);
• Effect on the endothelial function (increased production of NO) and 
on vascular reactivity (vasodilatation);
• Reduced production of cytokines by neutrophils and by monocytes;
• Strong anti-platelet effect (antithrombotic effect) and anti-
inflammatory;
• Inhibition of the atherosclerosis process.  
 
7.2 Long-Chain Polyunsaturated Fatty Acids (LC-PUFA)
Long-chain polyunsaturated fatty acids (LCPUFA) are the main components 
of cellular membranes, where they have an essential practical function as 
well as a structural one. Indeed they regulate the fluidity of the membranes 
as well as enzymatic, transport and receptor activity, and thus being the 
precursors of intra and intercellular mediators. 
These fatty acids derive from n-3 and n-6 essential fatty acids, α-linoleic 
acid and linoleic acid, and they include the eicosapentaenoic acid (20:5 n-
3, EPA), the docosahexaenoic acid (22:6 n-3, DHA) and the arachidonic 
acid (20:4 n-6, AA). The limiting stage for polyunsaturated fatty acids is 
caused by the action of delta-6 desaturase, the first enzyme operating on 
essential fatty acids from all series, for the synthesis of derivates (Figure12). 
It used to be believed that on the metabolic path leading to DHA synthesis 
there was a succession of three enzymatic activities called respectively 
delta 6, delta 5 and delta 4 desaturase, the latter in the final stage of DHA 
synthesis. However today there is reason to think that DHA synthesis occurs, 
if not univocally, at least mainly along a different path which is also more 
challenging from a biochemical standpoint. DHA synthesis is likely to involve 
two subsequent elongating stages, a new desaturation in Δ6 position and a 
β-oxidation in the peroxisomal see (Sprecher H, 2000). The direct proof of 
this mechanism was provided by congenital pathologies with the absence 
of peroxisomes, such as Zellweger Syndrome which are characterized by 
significant DHA deficits. 
It is important highlighting that despite human beings can elongate the 
chain of the α-linoleic acid introduced through the diet, transforming it in 
an eicosapentaenoic acid and in a docosahexaenoic acid (n-3 long-chain 
 
polyunsaturated fatty acids) the synthesis may not be sufficient to cater for 
the daily physiological need, and it is therefore recommended to introduce in 
the diet food containing these fatty acids. 
Currently in western world diets, the predominant polyunsaturated fatty 
acids are the ones from the n-6 series, made of the linoleic acid and the 
arachidonic acid. In the last 100 years the proportion between n-3 and n-
6 polyunsaturated fatty acids in western nutrition has deeply changed as 
these two families of polyunsaturated fatty acids share the same metabolic 
path, and this caused apprehension for potential health risks. However it is 
growingly clear how n-3 and n-6 have independent healthy effects on the 
body, and as the intake of n-6 is included in the recommended parameters, 
any possible preoccupations concerning the n-6:n-3 ratio are ascribable 
to a modest intake of n-3 instead of an excess of n-6. The said unbalance 
obviously affects the many molecules deriving from such precursors, bringing 
to a greater formation of metabolites deriving from AA (arachidonic acid). 
Prostaglandins formation happens through a competition between AA and 
n-3, EPA in particular, at cyclooxygenase and lipoxygenase level. The 
increased intake of n-3 fatty acids reduces the incorporation of AA within 
cellular membranes fostering a sharp anti-inflammatory response. Generally 
eicosanoids deriving from arachidonic acid PGE2, LTB4, TBX2, have 
inflammatory effects, and in particular the 12-hydroxyeicosatetraenoic acid 
(12-HETE) has a positive correlation with carcinogenesis. 
Eicosanoids deriving from EPA, series 3 prostaglandins and thromboxanes 
and series 5 prostaglandins and leukotrienes, reduce the production of AA 
and thus of AA-derived eicosanoids and they also increase their catabolism 
through the activity of peroxisomal enzymes. Furthermore they inhibit COX-
2 activity. A diet providing an intake of n-3 in the human body leads to a 
decrease of inflammatory markers such as leukotrienes, prostaglandins, 
interleukins and TNF (Table 3). 
 
 
 
 
 
 
TABLE 3. Effects of omega-3 fatty acid on inflammatory markers
 
 
 
 
More specifically this leads to: 
• A reduced production of prostaglandins E2 metabolites;
• Decrease of thromboxane A2, a strong vasoconstrictor and platelet 
aggregator and thus causing a thrombotic effect; 
• Reduced formation of leukotrienes B4, a potent inducer of 
inflammation and chemotaxis and leucocytes adherence; 
• An increase of thromboxane A3, a weak platelet aggregator and 
weak vasoconstrictor; 
• An increase of prostacyclin PGI3, a vasodilator and platelet 
aggregation inhibitor; 
• An increase of leukotrienes B5, a weak inflammation inducer and a 
weal chemotactic agent. 
Recent research highlighted how the production of lipid mediators with an 
anti-inflammatory function is not a prerogative only of EPA but also of DHA. 
 
In particular two new DHA deriving molecules were pointed out: docostrienes 
(10-17S docosatriene) and 17S resolvins (as they were identified during 
the resolution stage of acute inflammation). These molecules are found in 
the brain of the mouse, in human glial cells and in blood cells. They have 
an anti-inflammatory and an immunoregulatory effect for the role played 
regulating neutrophils migration, for cytokines expression as well as for 
their neuroprotective function. For these reasons they are also defined 
neuroprotectine. 
Besides the anti-inflammatory effect, n-3 fatty acids also have anti-
thrombotic, antiarrythmic and antiatherogenic functions. The stabilization 
of the cardiac tissue membrane determined by n-3 provides a potential 
antiarrythmic effect whilst the decrease of triglycerides is caused by the 
reduction and secretion of VLDL by the liver. 
Contrary to EPA, in the brain and in the retina there are plentiful AA and 
DHA. Polyunsaturated long-chain fatty acids are built in the phospholipids 
structure of cellular membranes where besides their generic structural 
function for a greater or lower fluidity, they also work for a wide range of 
membrane functions. The most significant example is provided by DHA, 
which is available with a high concentration (30-50%) in the membranes of 
the external segments of rod cells in the retina, where it regulates the activity 
of rhodopsin which is a protein photopigment assigned to vision in conditions 
of low brightness. 
The interaction between DHA and rhodopsin determines the hyper-
polarization of the plasma membrane generating the necessary nervous 
response for an optimal vision. DHA is also present at cerebral level in 
the aminophospholipid of cellular membranes of neurons, in the plasma 
membranes of synaptosome and of synaptic vesicles, where it plays 
a preferential role for the mediation of biochemical activities allowing 
neurotransmission. Glial cells care for the synthesis of DHA which is 
released in extra-cellular space and thus stored in neuronal cells. Any 
process jeopardizing the ability of glial cells to synthesize DHA, may 
compromise the structure and the function of nerve cells. Examples of this 
are provided by severe genetic diseases, such as Zellweger syndrome and 
neonatal adrenoleukodystrophy which present scarce DHA plasma levels 
caused by the inefficiency of β-3-oxidation at the end of the synthesis. The 
aforementioned pathologies are characterized by cerebral demyelination, 
adrenal atrophy and accumulation of fatty acids in the white matter of 
the adrenal cortex. Their evolution is an alteration of CNS, blindness and 
precocious death. 
 
The remarkable diffusion of LCPUFA in brain cells led to believe that 
the presence and the quantity of such elements in the diet can affect the 
cognitive function and behaviour. Although the research in the field is at 
the beginning stages, there are proofs, though minimal, suggesting an 
improvement of the cognitive function following the supplementation of fatty 
acids (Ryan AS et al., 2010). Indeed it was established that during pregnancy 
and breast-feeding, women should ensure a satisfying intake of n-3 long-
chain polyunsaturated fatty acids, to foster the growth, the neurological 
development and the cognitive function of the child. n-6 polyunsaturated 
fatty acids are more plentiful in diets, thus meeting the required need is less 
problematic. For n-3s the situation is different. 
Furthermore, a hypothesis has been put forward connecting the intake 
of unsaturated fatty acids and the course of a number of diseases, even 
though evidences are not yet conclusive the hypothesis does not cease 
to raise interest. Unsaturated fatty acids could be associated to a reduced 
risk of developing certain types of cancer such as colorectal cancer, breast 
cancer and prostate cancer (Brasky TM et al., 2012; Moore MR et al., 
2012). However at the moment the evidences supporting this connection 
are considered insufficient to justify nutritional recommendations from 
authoritative bodies. Many inflammatory conditions such as asthma, Crohn’s 
disease and arthritis, in theory could be alleviated with diet changes. 
The fatty acid composition of cellular membranes can be altered with the 
consumption of n-3 and n-6 polyunsaturated fatty acids, reducing the 
inflammatory activity. However it is not yet clear whether this effect goes 
together with a significant reduction of clinical symptoms. 
 
7.3 Docosahexaenoic acid (DHA)
DHA (22:6 n-3 or docosahexaenoic acid) is an essential fatty acid of the n-3 
series. The chemical structure is made of 22 atoms of carbon, with six double 
bonds spread along the structure, the first bond connects the third and the 
fourth carbon starting from the methyl section (ending section), from which 
derives the name ω3 (Figure 13). 
 
 
 
FIGURE 13. DHA
 
 
 
 
DHA is available in reasonable quantities in fish, particularly in salmon, 
mackerel, sardines, herrings, tuna and anchovies (oily fish). DHA can be 
found in even greater percentages in the oils derived from these animals, and 
obviously it can also be found in some micro-algae eaten by fish. Besides 
these fish and algae, the food sources of DHA are particularly scarce, it can 
be found in small quantities in meat especially when the animal was fed 
with fish meal or linen seeds (in this case, it is also available in the eggs 
of oviparous animals such as chickens). Proving its essential role for the 
human body, DHA is also present in breast–milk whilst it is absent in cow 
milk, in milk derivates and in vegetable oils. This observation gave origin 
to the recent practice of integrating the diet of pregnant and breast-feeding 
women with DHA, to guarantee the correct development of cerebral tissue, 
visual sharpness and cognitive abilities of the foetus and of the infant. Many 
industries specialized in the production of milk add DHA to their products to 
make its composition closer to that of human milk. 
On a nutritional level, the most renowned feature of docosahexaenoic acid 
concerns the proven capacity to reduce triglycerides in the blood. Therefore 
an adequate intake of DHA contributes to reducing the risk of cardiovascular 
disease, especially of thrombotic and atherosclerotic events. Low levels 
of DHA were related to neurological disease such as Alzheimer’s disease, 
depression (low levels showed reduced percentages of serotonin at brain 
level) and attention deficit hyperactivity disorder (ADHD). 
DHA is the main constituent of the phospholipids of the retina (it is used 
for the treatment of subjects affected by retinitis pigmentosa) and of brain 
synapses, and it is also concentrated in sperm cells and in the cardiac tissue. 
DHA guarantees the permeability and functionality of cellular membranes, 
contrasting the arachidonic acid (another polyunsaturated fatty acid that 
originates the so called “inflammatory cascade”). Docosahexaenoic acid was 
indeed ascribed anti-inflammatory properties, which justify its use to soothe 
the symptoms of rheumatoid arthritis and of ulcerative colitis. 
From a metabolic standpoint, DHA can be considered a semi-essential fatty 
acid. It is indeed synthesized by the human body from the alpha-linoleic 
 
acid (ALA), an essential fatty acid contained in fish, linen oil, hemp oil, colza 
oil, nuts and soy. However the enzymatic system operating this conversion 
may be inefficient in part, especially due to western life style and to its 
repercussions (diet rich of n-6 but poor of n-3, sedentary activities, excess of 
foods, fostering metabolic disease such as diabetes and obesity). The semi-
essentiality or essentiality of DHA (depending on the authors) at nutritional 
level is thus based on these assumptions. 
 
7.4 Long-chain fatty acids in essential obesity
In adults, the influence on metabolic syndrome, of fatty acids contained in the 
diet, has been repeatedly studied (Galgiani JE et al., 2008; U.S. Department 
of Agricolture and U.S. Department of Health and Human Services, 2010). 
Instead for paediatric age, the relationship between plasma polyunsaturated 
fatty acids and adiposity was scarcely investigated and it even produced 
contradictory results (Decsi T et al., 1998; Ailhaud G & Guesnet P, 2004; 
Okada T et al., 2005). 
The importance of LCPUFA derives from evidence showing how their 
derivates, prostaglandins, play an essential role in adipocyte differentiation 
(Reginato MJ et al., 1998). Decsi et al. published a study on long-chain 
fatty acids on the paediatric obese population (Decsi T et al., 1998). The 
study compares a group made of 22 paediatric obese patients with a group 
of normal weight patients of the same age and it highlights a significant 
increase of plasma values of n-6 series LCPUFA in the obese population. 
This significant increase is connected to a greater activity of the delta-6 
desaturase enzyme, and it is suggested that the high insulin levels registered 
for the obese population can stimulate the synthesis of n-6 LC-PUFA. 
A further study carried out in 2005 by Okada (Okada T et al., 2005) on 
59 obese children and on a control group made of 53 normal weight 
patients of the same age, accentuated a relationship between the plasma 
content of palmitoleic acid and abdominal obesity in obese children. This 
study suggests a possible connection between the profile modification of 
monounsaturated fatty acids (MUFA) and a hyper-activation of the Stearoyl-
Coa desaturase enzyme, which is not sufficiently suppressed by leptin. In 
conclusion the study ascribes to endogenous lipogenesis an important role in 
the pathogenesis of obesity in children.
A recent study conducted in our Paediatric Clinic showed that obese children 
have lower plasma levels of LCPUFA in comparison to normal weight 
ones, even though they appear to have a higher daily intake of all fatty 
acids families through diet, PUFA included. In particular, obese children, 
in comparison to normal weight ones, showed a significant increase of n-6 
 
series LCPUFA plasma levels and lower levels of DHA matched with higher 
levels precursors, alpha-linoleic (C18:3 n-3 or ALA ) and EPA. Although 
this difference could be partially explained by the different intake of fatty 
acids through the diet, it cannot be ruled out that in obese children there is 
a metabolic alteration on n-3 series synthesis path. This in consideration of 
the fact that the ratio DHA/ALA (indicating n-3 series activity) resulted lower 
in obese children than in normal weight ones. Plasma levels of C18:2n-6 
(linoelic acid) also resulted lower in obese children, whereas no differences 
were found between obese children and normal weight ones for what 
concerns C20:4 n-6(AA) values. Indeed like for other hypothesis it cannot 
be ruled out that lower plasma levels of C22:6n-3 (DHA) in obese children 
may mirror a greater contribution to the creation of hyperplastic tissues or a 
greater distribution in adipose tissue.  
Furthermore the BMI z-score of the sample population resulted negatively 
connected to DHA levels and positively related to the plasma ratio of n-6/n-3 
LCPUFA (AA/DHA). These results suggest that in obese children there may 
be both a relative PUFA deficit of n-6 series and an altered synthesis of DHA, 
in comparison to normal weight children. Indeed obese children with a higher 
BMI value have a different plasma pattern of fatty acids, to normal weight 
children and to obese ones with a lower BMI level. These further results 
suggest that the profile of plasma fatty acids could be directly correlated to 
the level of obesity at paediatric age (Scaglioni S et al, 2006). Furthermore, 
the study allowed understanding how an adequate nutritional intervention can 
positively affect the pattern of plasma fatty acids. After a year of nutritional 
education, there were evidences of increased levels of monounsaturated fatty 
acids, of n-6 andn-3 series PUFA, of C20:4N-6 (AA), of C22:6n-3(DHA), of 
the ratio C22:6n-3(DHA)/C20:4n-6(AA) and C22:6n-3(DHA)/C18:3n-3(ALA); 
and a reduction of saturated levels and of C20:3n-9.
 
7.5 LC-PUFA, insulin-resistance and liver steatosis
LCPUFA are important components of cellular membranes. Low levels of 
LCPUFA, especially of DHA, and a high intake of n-6/n-3 LCPUFA in the 
phospholipids of the membrane at skeletal muscle level were connected 
to the metabolic condition of insulin-resistance, which is one of the factors 
fostering the beginning of liver steatosis (Figure 14). 
 
 
 
FIGURE 14. Possible associations between fatty acids and metabolic 
condition of insulin-resistance
 
 
 
 
 
 
 
Furthermore, it is important to consider the effects of LCPUFA in modulating 
the expression of a number of genes dedicated to the regulation of insulin-
resistance and of lipid and carbohydrate metabolism. LCPUFA indeed 
would affect the modulation of the genetic expression of the PPARγ, which 
is a renowned factor of transcription involved in adypocyte differentiation, 
adipogenesis and insulin sensitivity, fostering the synthesis of adiponectin by 
the adipocyte (Figure 15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 15. Effects of LCPUFA on the modulation of the genetic expression 
of the PPARγ
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More specifically, an imbalance of the n-3/n-6 LCPUFA ratio towards the n-6 
series would lead to lower levels of adiponectin produced by the adipocytes, 
reducing the expression of the PPARγ gene, thus fostering the beginning of 
an insulin-resistance condition. As far as the hepatic tissue is concerned, a 
Chilean study of 2004 evaluated the pattern of LCPUFA in adults affected 
by liver steatosis and steatohepatitis registering a significant decrease of 
n-3 series LCPUFA levels in the adipose tissue and an increase of the 
n-6/n-3 LCPUFA ratio both in the phospholipids fraction at hepatic level 
and in the overall lipids of the adipose tissue. Moreover, according to this 
study, the low percentage of n-3 series LCPUFA would induce the down-
regulation of the protein SREBP 1 expression, which lowers the stimulus 
for the oxidation of fatty acids, increasing the concentration at hepatocytes 
level. This mechanism together with a reduced release of triacylglycerol from 
hepatocytes, mediated by a diminished activation of PPARγ, which is itself 
induced by the reduction of n-3 series LCPUFA, could justify the transition to 
the condition of liver steatosis (Figure 15). 
 
Currently, the evidence supporting the positive effect of n-3 series LCPUFA 
on insulin-resistance and on liver steatosis come from epidemiological and 
clinical studies carried out on adults. Indeed it was recently observed in 
two randomized studies conducted on overweight and obese young adults, 
that the intake of n-3 LCPUFA is connected to an improvement of insulin-
resistance and of liver steatosis. 
The effects of the supplementation of n-3 LCPUFA on metabolic 
complications retrieved in essential obesity at paediatric age have 
not yet been evaluated. Similarly, the metabolic consequences of the 
aforementioned supplementation, specifically the type of individual answer 
related to each specific genotype, remain unknown. 
The pattern of plasma fatty acid also seems to be influenced by whether or 
not there is a condition of steatosis, as proved by the said Chilean study. 
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8. STUDY
 
8.1 Objectives
Primary:
• To verify whether the supplementation of DHA, together with 
a dietary and behavioural intervention proves more efficient in 
improving the most frequent metabolic complication of childhood 
obesity, insulin-resistance, in comparison to a mere dietary and 
behavioural intervention.
Secondary:
• To reduce liver steatosis in the group supplemented with DHA. 
 
8.2 Population
The present longitudinal double-blind randomized study recruited a total of 
30 children, aged 8-13 years old, 14 boys (46.6%) and 16 girls (53.33%) 
affected by essential obesity, in the period between January 01, 2010 and 
September 30, 2012. 
All obese children consecutively admitted to the Department of Paediatrics, 
San Paolo Hospital, Milan, and to the Department of Paediatrics, Federico II 
Hospital, Naples. The said subjects accepted to be hospitalized for 2 days, 
for the evaluation of nutritional and life habits, carbohydrates metabolism, 
lipid profile, body composition and for an initial nutritional education program 
for the patients and their parents. Subjects were defined obese according to 
the classification provided by the International Obesity Task Force (Cole TJ 
et al, 2000). 
Children underwent a dietary-behavioural intervention and they were 
randomized in two groups:
1) Group A: subjects taking a DHA supplement, dosage 500 mg/diem
2) Group B: subjects taking wheat germ oil supplement (placebo). 
The dosage of DHA was established so to provide 2.4 grams of DHA/1000 
Kcal, which is ca. 2% of the daily caloric need. 
The said children were observed over a period of 6 months. 
Inclusion criteria are:
• Age between 8-13 years old
• Gestational age between 37 and 42 weeks
• Weight at birth ≥2500 gr and ≤ 4000 gr
• Absence of twins
• Caucasian race
• Obesity according to the International Obesity Task Force (IOFT)
 
• Insulin-resistance (fasting insulinaemia >15 uU/ml) according to the 
Italian Paediatrics Association (Società Italiana di Pediatria, 2006) 
• Presence or absence of liver steatosis
• Normolipidemia
Exclusion criteria are:
• Secondary obesity 
• Alteration of carbohydrate and insulin metabolism and/or fatty liver 
disease when not secondary to obesity. 
• Intestinal malabsorption, chronic inflammatory pathologies of the 
alimentary canal
Children’s parents received detailed information concerning the objectives 
pursued with the study and the evaluations that would have been carried out 
on children, for them to sign their consent to the study. The ethical committee 
of the University of Milan and of San Paolo Hospital in Milan approved the 
study’s protocol.
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9. MATERIALS AND METHODS
For the present longitudinal double-blind randomized study, recruited 
subjects were evaluated for a time period of 6 months. 
Before supplementation and after 6 months of observation, the evaluations 
were as follows:
1. Clinical examination and growth evaluation including weight and 
height, body circumference (arm, waist) as well as skinfolds (biceps 
and triceps, subscapular and suprailiac) measurement, evaluation 
of the general clinical conditions of the child through paediatric 
control and recording of arterial pressure with DINAMAP. Search for 
possible clinical signs of insulin-resistance (acanthosis nigricans).
2. Evaluation of nutritional habits, with the guidance of a dietician, 
according to patient’s answers, with the help of a parent, to 
questionnaires on food frequency (for a semi-quantitative evaluation 
of the child’s nutrition as well as of the variety of his/her diet).
3. Blood samples for a metabolic-nutritional evaluation and to assess 
the inflammatory condition: 
§ Complete blood count (CBC)
§ Fasting glucose and insulinaemia
§ Glycated haemoglobin
§ Triglyceridemia
§ Cholesterolaemia (total, HDL, LDL)
§ Apoliprotein A and B levels
§ Hepatic functions (AST, ALT, GGT).
Samples were taken on a blood level of ca. 10 ml and tests were 
carried out in the local laboratory.  
4. Electrocardiogram (ECG).
5. Abdominal ultrasound to study the possible presence of, and the thus 
extent of, fatty liver disease and to assess visceral and abdominal 
fat. 
6. Electrical bioimpedance (BIA) to analyze body composition. 
Anthropometric measurements were carried out by two paediatric doctors as 
provided by standard procedure. 
Weight was measured with a dedicated scale, either with bar and shifting 
weights one or with the electronic type. Accuracy is of 100g.
Height was measured with Harpenden stadiometer, with an accuracy of 0.1-
0.5cm. 
Tanner’s tables were recommended for weight and height evaluation 
reference. 
 
BMI was estimated by dividing the real weight of the child (in Kg) by the 
square of the stature in meters; the BMI z-score was calculated using Cole’s 
LMS method (Cole TJ, 1990) and Italian reference data (Cacciari E et al., 
2002). 
A tape measure was used to take body circumferences. The positioning of 
the tape measure for every different circumference is very important as it 
affects the reliability and precision of the measurement.
Waist circumference was measured with the method indicated by WHO 
in 1995, in the middle point between the last rib and the iliac crest which 
corresponds to the narrowest part of the abdomen (minimum circumference). 
The measure thus obtained was round up to the closest 0.1 cm. 
Skin-folds were evaluated according to standardized method, with Holtain 
Skinfold Calliper (Figure16). 
 
 
FIGURE 16. Holtain Skinfold Calliper
 
 
 
 
The tool’s quadrant is calibrated on 0.2 mm intervals, but measurement can 
be read up to 0.1mm.  
The triceps skinfold was measured on the posterior surface of the left arm, 
above the triceps muscle, at the midpoint of a line traced from the acromial 
process of the scapula and the lower margin of the olecranon process of the 
ulna. The site for the measurement was determined with a tape measure 
indicating the distance between the lateral projections of the acromial 
process and the lower edge of the olecranon process of the ulna, with the 
 
elbow bent at 90°. Once the midpoint was defined it was marked on the 
lateral surface of the arm. The operator lifted up the skinfold using the left 
thumb and the index, approximately 1 cm above the marked level and the 
extremities of the calliper were applied to it in correspondence of the marked 
level. 
Skin-folds and circumferences were measured according to Lohman 
(Lohman TG et al 1997). 
Parents’ weight and height were collected to calculate BMI. Parents were 
defined affected by overweight or obesity if BMI resulted higher than 25 kg/
m2 or 30 kg/m2  respectively. Two paediatricians calculated pubertal stages 
conforming to Tanner’s charts.  
The arterial pressure of each child was measured using a DINAMAP 
electronic manometer, using appropriate bracelets according to the size of 
the arm and it was evaluated on the basis of cut off levels defined for age, 
sex and height by the National High Blood Pressure Education Program 
Working Group on High Blood Pressure in Children and Adolescents.
Body composition was estimated with the bioimpedance method (BIA) with a 
TANITA scale. 
Blood sampling was performed in the morning, on an empty stomach. The 
evaluation considered lipid and carbohydrates profiles, hepatic functions, 
polyunsaturated fatty acids profile and ApoA and ApoB levels. 
Insulin blood levels were determined using the electrochemiluminescence 
method and glucose levels with enzymatic method. In conformance to the 
National Consensus for the prevention, diagnosis and therapy of obesity in 
the child and the adolescent (Società Italiana di Pediatria, 2006) basal insulin 
values above 15 μU/mL were considered diagnosis of insulin-resistance. 
Insulin-resistance and sensitivity were assessed using the HOMA-IR 
(Homeostasis Model Assessment of Insulin-Resistance Index) index 
calculation according to the following formula: 
                    [fasting insulinaemia (μU/l) x basal blood sugar (mmol/l)] 
 HOMA-IR=                                            
                                                            22.5
Children’s nutritional habits were evaluated through a Frequency Food 
Questionnaire (FFQ) targeted according to age and made of 116 items (Block 
G et al., 1986). The analysis of questionnaires and the nutritional breakdown 
was carried out using a program previously developed by the Paediatric 
Clinic of San Paolo Hospital based on the “Food and Nutrient Data Base” – 
Istituto Nazionale di ricerca per gli alimenti e la Nutrizione – (National Institute 
of research on food and nutrition) (INRNA)(Morales AE & Rosenbloom AL, 
2004). 
 
To assess the presence and the extent of fatty liver disease an expert 
radiologist carried out a liver ultrasound with a Hitachi H21 (Hitachi High 
Technology Corporation Ltd., Tokyo, Japan) using a 3.5–MHz transducer. 
Longitudinal, subcostal, ascendant and oblique scans were performed. Liver 
echogenicity was assessed using a video recording, by three independent 
radiologists who did not know the examined subject and then established the 
result by consensus. 
 
9.1 Test and statistical analysis 
The present study is presented as a longitudinal, randomized, double-blind 
trial. Descriptive data is expressed in terms of average, standard deviation 
(SD), median and variability interval (continuous variables) or for the number 
of cases examined and percentage (discrete variables). 
Tests performed:
1. Chi-square test on contingency tables
2. Mann-Whitney nonparametric test for two independent samples
3. Values of p < 0.05 were considered statistically significant; label 
“statistically significant tendency” referred to values between 0.10 
and 0.05. 
4. Statistical analysis was performed using the SPSS software version 
19.0 for Windows (SPSS Inc., Chicago, IL, USA).
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10. RESULTS
 
10.1 Characteristics of the population at baseline  
The present longitudinal, randomized, double-blinded study recruited 30 
children, of which 14 boys (47%) and 16 girls (53%), aged between 8 and 
13 years old (average age: 11 years and 4 months, SD 1.29) affected by 
essential obesity (Table 4). 
 
TABLE 4. Age and sex of participants.
 
 
 Children (n=30)
Age (years)
   Mean
   SD
   Median
   Minimum-maximum
 
11.40
1.2
11.0
8-13
Sex Girls: 16 (53%)
Boys: 14 (47%)
 
 
Average of anthropometric characteristics resulted as follows: 
- height 1.55 m (SD 0.08)
- weight 72.57 kg (SD 13.50)
- BMI 29.89 kg/m2 (SD 3.85)
- waist circumference 86.49 cm (SD 8.83)
- triceps skinfold 40.58 mm (SD 27.16)
All recruited subjects were at a pre-pubertal stage on the basis of the 
pubertal stage classification by Tanner (average stage 2.23, SD 0.89) (Table 
5).
 
 
 
 
 
 
 
 TABLE 5. Anthropometric characteristics of participants.
Children (n=30)
 Mean (SD) Median Minimum-
maximum
Height  (m)
Weight(Kg)
BMI (Kg/m2)
BMI z score
Waist circumference (cm)
Triceps skinfold (mm)
Tanner stage
 
1.55 (0.088)
72.57 (13.50)
29.89 (3.85)
2.26 (0.47)
86.49 (8.83)
40.58 (27.16)
2.23 (0.89)
 
1.56
75.55
28.88
2.23
88.20
34.00
 
 
1.41-1.70
48.70-94.00
24,50-36.58
1.44-3.00
68.50-99.00
21.00-139.00
1-4
 
 
 
 
The analysis of the data, derived from the breakdown of the food frequency 
questionnaire (FFQ) (Table 6) answered by examined subjects, shows an 
average caloric intake of 2735.46 kcal/die (SD 741.38), hereby divided for 
macronutrients classes: 
- proteins: 14.79% (SD 1.64), 99.82 g (SD 21.83)
- lipids: 30.78% (SD 2.75), 96.76 g (SD 32.78)
- carbohydrates: 53.75% (SD 3.29), 390.06 g (SD 100.21)
As far as the lipids intake in particular is concerned:
- saturated: 8.96% (SD 3.94), 27.32 g (SD 13.07)
- monounsaturated: 11.19% (SD 2.59), 34.07 g (SD 11.38)
- polyunsaturated: 2.78% (SD 0.19), 8.68 g (SD 3.09)
 
 
 
 
 
 
 
 TABLE 6. Total energy, macronutrients and fibre intake, overall glycemic 
index and glycemic load in participants.
Children (n=30)
 Mean (SD) Median Minimum-
maximum
Total energy (Kcal)
Total energy (KJ)
Proteins (%)
Proteins (g)
   Animal (g)
   Vegetal (g)
Lipids (%)
Lipids(g)
   Saturated (%)
   Saturated (g)
   Monounsaturated (%)
   Monounsaturated (g)
   Polyunsaturated (%)
   Polyunsaturated (g)
Carbohydrates (%)
Carbohydrates (g)
   Simple (g)
   Complex (g)
Fibre (g)
Overall glycemic index
Glycemic load
2735.46 (741.38)
11453.48 
(3103.09)
14.79 (1.64)
99.82 (21.83)
65.29 (18.95)
35.11 (8.31)
30,78 (2,75)
96.76 (32.78)
8.96 (3.94)
27.32 (13.07)
11.19 (2.59)
34.07 (11.38)
2.78 (0.19)
8.68 (3.09)
53.75 (3.29)
390.06 (100.21)
125.84 (50.98)
226.10 (58.59)
16.86 (4.83)
73.55 (16.30)
1215.75 (536.57)
 
2502.61
10477.99
14.42
94.23
58.83
38.15
30.50
84.56
7.61
20.69
11.90
29.29
2.71
7.51
54.86
348.15
116.61
228.27
17.53
72.46
1111.56
2036.26-
4355.09
8518.82-
18229.83
12.78-18.96
73.41-139.14
48.21-98.38
24.64-48.58
26.83-36.02
64.97-165.13
6.90-20.04
16.45-58.48
7.27-16.16
17.73-57.76
2.56-3.25
5.81- 15.26
47.72-58.41
308.46-616.83
59.67-228.02
160.36-340.77
8.14-23.10
43.26-93.04
524.86-2299.55
 
 
Blood profile showed presence of insulin-resistance in 28 subjects out of 30 
(93%) with average insulinaemia values equal to 21.82 µU/ml (SD 6.79).
As indicated in inclusion criteria, all recruited subjects presented a normal 
lipid profile at the beginning of the study. 
Average levels of hepatic function indexes resulted as follows: 
- ALT: 31.26 U/L (SD 19.03)
- AST: 27.20 U/L (SD 9.23)
 
- GGT: 13.40 U/L (SD 3.72)
Arterial pressure analysis showed average levels of systolic arterial pressure 
of 116.93 mmHg (DS 10.20) and of diastolic arterial pressure equal to 67.40 
mmHg (SD 8.92) (Table 7).
 
 
TABLE 7. Blood profile and blood pressure in participants.
 
 
 
 
 
 
Children (n=30)
 Mean (SD) Median Minimum-
maximum
Glucose (mg/dl) 
Insulin (µU/mL)
HOMA 
Glycated haemoglobin (%)
Total cholesterol (mg/dL)
   HDL (mg/dL)
   LDL (mg/dL)
Triglycerides  (mg/dL)
Total cholesterol/HDL
TG/HDL
ApoA (mg/dL)
ApoB (mg/dL)
ApoA/ApoB
ALT (U/l)
AST (U/l)
GGT  (U/l)
C-reactive protein (mg/L)
Blood pressure (mmHg)
   Systolic    
   Diastolic 
90.86 (17.32)
21.82 (6.79)
4.70 (1.20)
5.44 (0.21)
161.13 
(20.45)
46.13 (7.74)
92.60 (15.30)
97.36 (33.94)
3.55 (0.54)
2.19 (0.88)
107.96 
(14.55)
66.66 (6.68)
1.62 (0.16)
31.26 (19.03)
27.20 (9.23)
13.4 (3.72)
3.93 (4.97)
 
116.93 
(10.20)
67.40 (8.92)
86.00
20.45
4.52
5.45
162.00
44.50
90.00
94.00
3.61
2.21
104.00
66.00
1.63
27.00
23.50
12.00
1.00
 
118.00
67.00
68-137
12.50-32.60
2.57-6.85
5.10-5.80
122-197
35-58
59-113
55-182
2.75-4.84
1.05-3.95
93-142
53-81
1.35-1.92
12-82
20-51
8-19
0.33-15.00
 
100-135
54-85
Ultrasonography evaluation showed the presence of liver steatosis in 5 
subjects (17%), of which 3 patients also presented insulin-resistance (10%) 
(Table 8). 
 
 
TABLE 8. Distribution of steatosis and acanthosis in participants.
Children (n=30)
 n (%)
Steatosis (yes)         5 (17)
Acanthosis (yes)        20 (66) 
 
The overall population was double-blind randomised in 2 groups: 
1) Group A: subjects supplemented with DHA, dosage of 500 mg/die (2 
pearls) for 6 months
2) Group B: subjects supplemented with wheat germ oil (placebo) 2 
capsules/day for 6 months. 
DHA dosage was established so to provide 2.4 grams of DHA/1000 Kcal, 
which is ca.2% of the needed daily caloric intake. 
None of the subjects showed collateral effects caused by the administration 
of the substances prepared. 
 
Distribution of steatosis and acanthosis, anthropometric data, dietary 
composition, and blood profile, at baseline and at the end of the study, are 
described in tables 9-16, in the two groups separately  (A and B).
 
Group A ( DHA)
 
TABLE 9. Distribution of steatosis and acanthosis in DHA children, at 
baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 n (%) n (%) p§
Steatosis (yes) 2 (14) 1(7) 0.655
Acanthosis (yes)  10 (66) 1(7) 0.014*
 
§ Statistical significance between baseline and end of the study (Student t 
test for paired data or Wilcoxon test)
 
*Statistically significant
 
TABLE 10. Anthropometric characteristics of DHA children, at baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 Mean (SD) Median Min-Max Mean (SD) Median Min-Max P§
Height  (m)
Weight(Kg)
BMI (Kg/m2 )
BMI z score
Waist circumference (cm)
Triceps skinfold (mm)
1.55 (0.08)
72.28 (13.95)
29.89 (4.02)
2.25 (0.49)
86.59 (9.07)
40.62 (27.60)
 
1.56
73.60
28.60
2.17
88.20
34.40
 
1.41-1.70
48.70-94.00
24.50-36.58
1.44-3.00
68.50-99.00
21.00-139.00
 
1.57 (0.08)
72.08 (14.64)
28.95 (4.33)
1.90 (0.95)
86.57 (9.50)
31.84 (7.07)
 
1.58
68.20
27.90
1.93
84.50
3.00
 
1.47-1.73
46.20-99.80
22.00-35.79
0.04-3.02
68.00-102.50
21.00-40.00
 
0.002*
0.910
0.088
0.073
0.609
0.245
 
 
§ Statistical significance between baseline and end of the study (Student t test for paired data or Wilcoxon test)
*Statistically significant
 
TABLE 11. Dietary intake, overall glycemic index and glycemic load in DHA children, at baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 Mean (SD) Median Min-Max Mean (SD) Median Min-Max p§
Total energy (Kcal)
Total energy (KJ)
Proteins (%)
Proteins (g)
   Animal (g)
   Vegetal (g)
Lipids (%)
Lipids(g)
   Saturated (%)
   Saturated (g)
   Monounsaturated (%)
   Monounsaturated (g)
   Polyunsaturated (%)
   Polyunsaturated (g)
Carbohydrates (%)
Carbohydrates (g)
   Simple (g)
   Complex (g)
Fibre (g)
Overall glycolic index
Glycolic load
2801.24 (825.55)
11728.60 (3455.23)
14.68 (1.70)
101.24 (23.75)
66.51 (19.86)
35.42 (8.87)
30.87 (2.84)
99.42 (36.25)
8.94 (3.93)
27.86 (13.20)
10.94 (2.55)
34.04 (11.58)
2.80 (0.21)
9.00 (3.44)
53.99 (3.22)
400.97 (111.44)
134.62 (53.42)
229.44 (64.98)
16.68 (5.18)
75.75 (16.74)
1287.68 (585.48)
2502.61
10477.99
14.42
94.23
60.50
35.04
30.15
84.56
7.62
20.69
10.89
29.17
2.74
7.38
54.86
348.15
120.59
210.72
17.53
78.94
1193.58
2036.16-4355.09
8518.82-18229.83
12.78-18.96
73.41-139.14
48.21-98.38
24.64-48.58
26.83-36.02
64,97-165,13
6.90-20.04
16.45-58.48
7.27-16.16
17.73-57.76
2.56-3.15
5.81- 15.26
47.72-58.41
308.46-616.83
59.67-228.02
160.36-340.77
8.14-23.10
43.26-93.04
524.86-2299.55
2470.85 (418.62)
10343.97 (1754.71)
20.23 (5.09)
124.55 (35.01)
90.77 (37.18)
33.78 (7.57)
25.34 (4.32)
72.28 (14.03)
7.61 (1.98)
20.58 (4.95)
8.38 (1.22)
22.79 (3.85)
2.73 (0.77)
7.62 (3.01)
53.07 (6.86)
350.97 (78.22)
113.06 (43.47)
195.06 (45.96)
21.20 (6.24)
62.15 (29.17 )
1080.43 (639.76)
2450.67
10261.95
18.98
118.42
85.79
32.11
25.69
68.22
7.65
20.91
8.38
23.30
2.58
7.52
52.84
360.17
98.44
193.25
21.76
62.97
923.88
1864.84-3260.61
7802.06-13655.46
14.27-33.01
81.65-188.54
35.58-159.48
24.63-53.45
17.51-31.63
53.23-101.24
3.72-11.56
10.31-26.93
5.73-9.90
15.90-28.10
1.93-4.31
4.43-14.37
40.67-66.46
23.02-459.69
64.16-183.93
115.64-255.17
7.85-33.62
10.54-119.27
423.02-2440.18
0.507
0.507
0.007*
0.092
0.059
0.646
0.012*
0.022*
0.646
0.139
0.028*
0.022*
0.576
0.444
0.959
0.386
0.575
0.284
0.059
0.168
0.444
§ Statistical significance between baseline and end of the study (Student t test for paired data or Wilcox on test). *Statistically significant
 
TABLE 12. Blood profile and blood pressure in DHA children, at baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 Mean (SD) Median Min-Max Mean (SD) Median Min-Max p§
Glucose (mg/dl)
Insulin (µU/mL)
HOMA 
Glycated haemoglobin (%)
Total cholesterol (mg/dL)
   HDL (mg/dL)
   LDL (mg/dL)
Triglycerides  (mg/dL)
Total cholesterol /HDL
TG/HDL
ApoA (mg/dL)
ApoB (mg/dL)
ApoA/ApoB
ALT (U/l)
AST (U/l)
GGT  (U/l)
C-reactive protein (mg/L)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
89.86 (18.04)
21.52 (6.85)
4.58 (1.21)
5.42 (0.22)
160.46 (20.86)
45.26 (7.25)
92.93 (15.62)
97.46 (34.67)
3.59 (0.53)
2.22 (0.88)
106.88 (13.21)
66.20 (6.27)
1.61 (0.16)
30.06 (16.53)
26.60 (8.95)
13.26 (3.53)
4.39 (5.42)
115.73 (9.98)
67.33 (8.07)
86.00
20.00
4.12
5.40
162.00
44.00
90.00
94.00
3.82
2.21
104.00
66.00
1.63
27.00
23.00
12.00
1.00
111.00
67.00
68.00-137.00
12.50-32.60
2.57-6.85
5.10-5.80
122.00-197.00
35.00-58.00
59.00-113.00
55.00-182.00
2.75-4.84
1.05-3.95
93.00-142.00
53.00-81.00
1.35-1.92
12.00-82.00
20.00-51.00
8.00-19.00
0.33-15.0
100-135
54-85
84.13 (9.91)
14.07 (4.58)
3.05 (1.06)
5.36 (0.32)
145.80 (22.15)
45.73 (9.84)
84.13 (16.89)
70.60 (15.73)
3.25 (0.50)
1.61 (0.46)
107.00 (13.03)
65.66 (13.10)
1.66 (0.24)
25.73 (9.68)
24.33 (6.42)
13.73 (6.76)
3.20 (2.58)
115.53 (10.48)
66.73 (11.43)
86.00
13.80
3.12
5.4
151.00
45.00
79.00
69.00
3.17
1.68
101.00
62.00
1.68
24.00
23.00
11.00
4.00
114.00
70.00
71.00-105.00
2.00-34.80
0.46-6.38
4.80-5.90
111.00-
187.00
35.00-62.00
65.00-122.00
48.00-105.00
2.48-4.07
0.79-2.28
94.00-132.00
55.00-108.00
1.22-2.08
10.00-46.00
17.00-38.00
9.00-36.00
0.33-6.60
100-131
50-80
0.054
0.001*
0.001*
0.422
0.031*
0.777
0.061*
0.002*
0.041*
0.020*
0.623
0.220
0.078
0.299
0.081
0.693
0.649
0.806
0.845
§ Statistical significance between baseline and end of the study (Student t test for paired data or Wilcoxon test). *Statistically significant 
 
Group B (placebo) 
 
TABLE 13. Distribution of steatosis and acanthosis in placebo children, at 
baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 n (%) n (%) P§
Steatosis 3 (20) 2 (13) 0.276
Acanthosis 9 (60) 3 (18) 0.025*
 
§ Statistical significance between baseline and end of the study (Student t 
test for paired data or Wilcoxon test)
* Statistically significant
 
TABLE 14. Anthropometric characteristics of placebo children, at baseline (T=0) and at the end of the study (T=1)
 
 
 
 T0 (n=15) T1 (n=15)  
 Mean (SD) Median Min-Max Mean (SD) Median Min-Max P§
Height  (m)
Weight(Kg)
BMI (Kg/m2 )
BMI zscore
Waist circumference (cm)
Triceps skinfold (mm)
 
1.55 (0.09)
72.86 (13.53)
29.89 (3.81)
2.27 (0.47)
86.39 (8.89)
40.54 (27.68)
 
1.57
77.50
29.16
2.29
88.20
34.40
 
1.41-1.70
48.70-94.0
24.50-36.58
1.44-3.00
68.50-99.00
21.00-139.00
 
1.57 (0.08)
73.54 (15.49)
29.18 (4.47)
1.95 (0.96)
86.80 (9.76)
31.54 (7.25)
 
1.59
74.80
29.50
2.16
85.50
33.00
 
1.45-1.73
46.20-99.80
22.00-35.79
0.04-3.02
68.00-102.50
21.00-40.00
 
0.003*
0.649
0.233
0.198
0.865
0.140
 
 
§ Statistical significance between baseline and end of the study (Student t test for paired data or Wilcoxon test)
*Statistically significant
 
 
TABLE 15. Dietary intake, overall glycemic index and glycemic load in placebo children, at baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 Mean (SD) Median Min-Max Mean (SD) Median Min-Max p§
Total energy (Kcal)
Total energy (KJ)
Proteins (%)
Proteins (g)
   Animal (g)
   Vegetal (g)
Lipids (%)
Lipids(g)
   Saturated (%)
   Saturated (g)
   Monounsaturated (%)
   Monounsaturated (g)
   Polyunsaturated (%)
   Polyunsaturated (g)
Carbohydrates (%)
Carbohydrates (g)
   Simple (g)
   Complex (g)
Fibre (g)
Overall glycemic index
Glycemic load
2663.09 (673.09)
11150.83 (2817.58)
14.90 (1.65)
98.26 (20.66)
63.94 (18.98)
34.76 (8.16)
30.69 (2.79)
93.83 (30.16)
8.97 (4.19)
26.72 (13.70)
11.46 (2.75)
34.10 (11.84)
2.75 (0.18)
8.33 (2.80)
53.49 (3.51)
378.06 (90.63)
116.08 (49.35)
222.39 (54.25)
16.94 (4.70)
71.10 (16.42)
1135.84 (498.51)
2502.61
10477.99
14.60
91.25
58.83
38.15
30.27
86.20
7.61
19.62
11.09
29.29
2.70
7.51
53.98
341.53
109.96
228.27
17.89
68.67
1035.12
2036.16-4355.09
8518.82-18229.83
12.78-18.96
73.41-139.14
48.21-98.38
24.64-48.58
26.83-36.02
64.97-165.13
6.90-20.04
16.45-58.48
7.27-16.16
17.73-57.76
2.56-3.15
5.81-15.26
47.72-58.41
308.46-616.83
59.67-228.02
160.36-340.77
8.14-23.10
43.26-93.04
524.86-2299.55
2416.55 (474.84)
10116.36 (1990.54)
20.73 (5.35)
124.54 (36.95)
91.02 (39.23)
33.51 (8.07)
25.90 (5.04)
72.20 (14.81)
7.71 (2.10)
20.30 (5.24)
8.27 (1.22)
21.97 (4.12)
2.78 (0.77)
7.64 (3.18)
51.82 (7.51)
336.38 (90.60)
111.03 (48.47)
182.06 (52.72)
20.73 (6.63)
59.88 (31.17)
1054.27 (701.73)
2406.33
10076.52
20.29
109.26
78.64
31.62
26.13
68.94
8.08
19.54
8.43
20.51
2.45
7.44
52.82
354.27
92.13
191.89
19.80
55.87
795.62
1864.84-3260.61
7802.06-13655.46
14.27-33.01
81.65-188.549
35.58-159.48
24.63-53.45
17.51-31.63
53.23-101.24
3.72-11.56
10.31-26.93
5.73-9,90
15.90-28.10
1.93-4.31
4.43-14.37
40.67-66.46
238.02-459.69
64.16-183.93
115.64-255.17
7.85-33.62
10.54-119.27
423.02-2440.177
0.374
0.374
0.011*
0.066
0.038*
0.678
0.050*
0.028*
0.859
0.260
0.021*
0.028*
0.859
0.441
0.678
0.314
0.859
0.213
0.066
0.260
0.767
§ Statistical significance between baseline and end of the study (Student t test for paired data or Wilcoxon test). *Statistically significant
 
TABLE 16. Blood profile and blood pressure in placebo children, at baseline (T=0) and at the end of the study (T=1)
 T0 (n=15) T1 (n=15)  
 Mean (SD) Median Min-Max Mean (SD) Median Min-Max p§
Glucose (mg/dl)
Insulin (µU/mL)
HOMA 
Glycated haemoglobin (%)
Total cholesterol (mg/dL)
   HDL (mg/dL)
   LDL (mg/dL)
Triglycerides (mg/dL)
Total cholesterol/HDL
TG/HDL
ApoA (mg/dL)
ApoB (mg/dL)
ApoA/ApoB
ALT (U/l)
AST (U/l)
GGT  (U/l)
C-reactive protein (mg/L)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
91.86 (17.14)
22.13 (6.96)
4.82 (1.22)
5.46 (0.21)
161.80 (20.75)
47.00 (8.35)
92.26 (15.51)
97.26 (34.40)
3.50 (0.57)
2.16 (0.91)
109.06 (16.17)
67.13 (7.26)
1.62 (0.16)
32.46 (21.76)
27.80 (9.77)
13.53 (4.03)
3.47 (4.61)
118.13 (10.61)
67.47 (9.98)
86.00
20.90
5.02
5.50
162.00
45.00
90.00
94.00
3.41
2.21
104.00
66.00
1.63
27.00
24.00
12.00
1.00
118.00
67.00
68.00-137.00
12.50-32.60
2.57-6.85
5.10-5.80
122.00-197.00
35.00-58.00
59.00-113.00
55.00-182.00
2.75-4.84
1.05-3.95
93.00-142.00
53,00-81,00
1.35-1.92
12.00-82.00
20.00-51.00
8.00-19.00
0.33-15.0
100-135
54-85
85.86 (9.51)
17.54 (5.07)
3.84 (1.46)
5.40 (0.30)
150.40 (19.10)
49.26 (10.13)
84.46 (16.68)
68.20 (17.20)
3.13 (0.55)
1.46 (0.51)
108.73 (13.58)
66.06 (12.87)
1.67 (0.27)
26.26 (11.73)
25.06 (7.48)
15.06 (8.92)
2.66 (2.61)
116.47 (9.27)
67.20 (10.57)
88.00
16.80
3.44
5.50
153.00
46.00
82.00
68.00
3.02
1.44
102.00
62.00
1.68
24.00
23.00
11.00
1.00
120.00
70.00
71.00-105.00
2.00-34.80
0.46-6.38
4.80-5.90
111.00-
187.00
35.00-62.00
65.00-122.00
48.00-105.00
2.48-4.07
0.79-2.28
94.00-132.00
55.00-108.00
1.22-2.08
10.00-46.00
17.00-38.00
9.00-36.00
0.33-6.60
100-131
50-80
0.059
0.048*
0.05*
0.388
0.041*
0.094
0.069
0.001*
0.012*
0.004*
0.637
0.220
0.078
0.123
0.016*
0.937
0.754
0.484
0.944
§ Statistical significance between baseline and end of the study (Student t test for paired data or Wilcoxon test). *Statistically significant    
 
Comparison between groups
 
Tables 17-21 compare the two groups (DHA vs. placebo) with regards to 
anthropometric data, blood profile, pressure and ultrasonography, both at 
baseline and at the end of the study. At analysis of repeated measures with 
treatment as fixed factor no significant difference was found between groups 
(minimum p=0.216). 
 
TABLE 17. Anthropometric characteristics of children (DHA vs. placebo), at 
baseline (T=0) and at the end of the study (T=1). Data are mean (SD).
 
 DHA (n=15) Placebo (n=15) P§
Height  (m)
   Baseline
   End of the study
   P§§
 
1,55 (1.41)
1,57 (0.08)
0.002* 
 
1.55 (0,09)
1.57 (0,08)
0.003*
 
0.806
0.838
 
Weight (Kg)
   Baseline
   End of the study
   P§§
 
72.28 (48.70)
72.08 (14.64)
0.910
 
72.86 (13.53)
73.54 (15.49)
0.649
 
0.870
0.806
BMI (Kg/m2)
   Baseline
   End of the study
   P§§
 
29.89 (4.02)
28.95 (4.33)
0.088
 
29.89 (3.81)
19.18 (4.47)
0.233
 
1.000
0.870
BMI z-score 
   Baseline
   End of the study
   P§§
 
2.25 (0.49)
1.90 (0.95)
0.078
 
2.27 (0.47)
1.95 (0.96)
0.198
 
0.935
0.902
Waist circumference (cm)
   Baseline
   End of the study
   P§§
 
86.59 (9.07)
86.57 (9.50)
0.609
 
86.39 (8.89)
86.80 (9.76)
0.865
 
0.902
0.902
Triceps skinfold (mm)
   Baseline
   End of the study
P§§
 
40.62 (27.60)
31.84 (7.07)
0.245
 
40.54 (27.68)
31.50 (7.25)
0.140
 
1.000
0.935
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  §§ Statistical significance of within 
group longitudinal variation (Student t test for paired data or Wilcoxon test).
* Statistically significant
 
Table 18. Glycemic profile of children (DHA vs. placebo), at baseline (T=0) 
and at the end of the study (T=1). Data are mean (SD)
 
 DHA (n=15) Placebo (n=15) P§
Glucose (mg/dl)
   Baseline
   End of the study
   P§§
 
89.86 (18.04)
84.13 (9.91)
0.054
 
91.86 (17.14)
85.86 (9.51)
0.059
 
0.713
0.512
Insulin (µU/mL)
   Baseline
   End of the study
   P§§
 
21.52 (6.85)
14.07 (4.58)
0.001*
 
22.13 (6.96)
17.54 (5.07)
0.048*
 
0.838
0.050*
HOMA 
   Baseline
   End of the study
   P§§
 
4.58 (1.21)
3.05 (1.06)
0.001*
 
4.82 (1.22)
3.84 (1.46)
0.05*
 
0.539
0.101
Glycated haemoglobin (%)
   Baseline
   End of the study
   P§§
 
5.42 (0.22)
5.36 (0.32)
0.422
 
5.46 (0.21)
5.40 (0.30)
0.388
 
0.624
0.683
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  §§ Statistical significance of within 
group longitudinal variation (Student t test for paired data or Wilcoxon test).
* Statistically significant
 
TABLE 19. Lipid profile of children (DHA vs. placebo), at baseline (T=0) and 
at the end of the study (T=1). Data are  mean (SD) 
 DHA (n=15) Placebo (n=15) P§
Total cholesterol (mg/dL)
   Baseline
   End of the study
   P§§
 
160.46 (20.86)
145.80 (22.15)
0.031*
 
161.80 (20.75)
150.40 (19.10)
0.041*
 
0.870
0.595
LDL cholesterol (mg/dL)
   Baseline
   End of the study
   P§§
 
92.93 (15.62)
84.13 (16.89)
0.061
 
92.26 (15.51)
84.46 (16.68)
0.069
 
0.935
0.902
HDL cholesterol (mg/dL)
   Baseline
   End of the study
   P§§
 
45.26 (7.25)
45.73 (9.84)
0.777
 
47.00 (8.35)
49.26 (10.13)
0.094
 
0.624
0.345
Triglycerides mg/dL)
   Baseline
   End of the study
   P§§
 
97.46 (34.67)
70.60 (15.73)
0.002*
 
97.20 (34.40)
68.20 (17.20)
0.001*
 
1.000
0.653
 
Total cholesterol /HDL
   Basale
   End of the study
   P§§
 
3.59(0.53)
3.25 (0.50)
0.041*
 
3.50 (0.57)
3.13 (0.55)
0.012*
 
0.653
0.539
Triglycerides/HDL
 Baseline
 End of the study
P§§
 
2.22 (0.88)
1.61 (0.46)
0.020*
 
2.16 (0.91)
1.46 (0.51)
0.004*
 
0.838
0.436
ApoA (mg/dL)
 Baseline
 End of the study
P§§
 
106.86 (13.21)
107.00 (13.03)
0.623
 
109.06 (16.17)
108.73 (13.58)
0.637
 
0.870
0.775
ApoB (mg/dL)
Baseline
 End of the study
P§§
 
66.20 (6.27)
65.66 (13.10)
0.220
 
67.13 (7.26)
66.06 (12.87)
0.220
 
0.806
0.838
ApoA/ApoB 
Baseline
End of the study
P§§
 
1.61 (0.16)
1.66 (0.24)
0.078
 
1.62 (0.16)
1.67 (0.27)
0.078
 
0.838
0.902
§ Statistical significance of difference between groups (Student t test for independent data 
or Mann-Whitney U test).  §§ Statistical significance of within group longitudinal variation 
(Student t test for paired data or Wilcoxon test). * Statistically significant 
 
TABLE 20. Hepatic function indicators of children (DHA vs. placebo), at 
baseline (T=0) and at the end of the study (T=1). Data are  mean (SD)
 DHA (n=15) Placebo (n=15) P§
ALT (U/L)
 Baseline
End of the study
   P§§
 
30.06 (16.53)
25.73 (9.68)
0.299
 
32.46 (21.76)
26.26 (11.73)
0.123
 
0.935
0.935
AST (U/L)
 Baseline
End of the study
   P§§
 
26.60 (8.95)
24.33 (6.42)
0.081
 
27.80 (9.77)
25.06 (7.48)
0.016*
 
0.870
1.000
GGT (U/L)
 Baseline
End of the study
   P§§
 
13.26 (3.53)
13.73 (6.76)
0.693
 
13.53 (4.03)
15.06 (8.92)
0.937
 
0.935
1.000
Steatosis 
Baseline
End of the study
P§§
 
0.27 (0.467)
0.27 (0.90)
1.000
 
0.30 (0.483)
0.60 (1.26)
0.276
 
0.918
0.705
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  §§ Statistical significance of within 
group longitudinal variation (Student t test for paired data or Wilcoxon test).
* Statistically significant
 
 
TABLE  21. Blood pressure and C-reactive protein of children (DHA vs. 
placebo), at baseline (T=0) and at the end of the study (T=1). Data are  
meaning (SD)
 
 DHA (n=15) Placebo (n=15) P§
Systolic blood pressure ( (mmHg)
Baseline
End of the study
   P§§
 
115.73 (9.98)
115.53 (10.48)
0.806
 
118.13 (10.61)
116.47 (9.27)
0.484
 
0.512
0.838
Diastolic blood pressure  (mmHg)
Baseline
End of the study
   P§§
 
67.33 (8.07)
66.73 (11.42)
0.888
 
67.47 (9.98)
67.20 (10.57)
0.944
 
0.935
0.902
C-reactive protein (mg/L)
 Baseline
End of the study
   P§§
 
4.39 (5.42)
3.20 (2.58)
0.649
 
3.47 (4.61)
2.66 (2.61)
0.754
 
0.838
0.713
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  §§ Statistical significance of within 
group longitudinal variation (Student t test for paired data or Wilcoxon test).
* Statistically significant
 
 
 
 
No significant difference was found between groups with regards to 
longitudinal percentage variation [(end of study – baseline)*100/baseline] for 
any variable except insulin (p=0.046) and HOMA (p=0.045) (Tables 22-26) 
 
TABLE 22. Percentage variation of anthropometric characteristics in DHA 
and placebo groups. Data are mean (SD)
 
 
 DHA
(n=15)
Placebo
(n=15)
P§
Height  (m) 0.013 (0.011) 0.014 (0.012) 0.775
Weight (Kg) -0.002 (0.071) 0.007 (0.076) 0.653
BMI (Kg/m2) -0.031 (0.067) -0.024 (0.074) 0.838
BMI zscore -0.172 (0.355) -0.159 (0.363) 0.806
Waist circumference (cm) 0.001 (0.073) 0.006 (0.073) 0.806
Triceps skinfold (mm) -0.083 (0.259) -0.091 (0.251) 1.000
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  
 
 
TABLE 23. Percentage variation of glycemic profile in DHA and placebo 
groups. Data are mean (SD)
 
 
 DHA +
(n=15)
Placebo +
(n=15)
P§
Glucose (mg/dl) -0.047 (0.105) -0.050 (0.109) 0.838
Insulin (µU/mL) -0.346 (0.230) -0.207 (0.117) 0.046*
HOMA -0.334 (0.213) -0.203 (0.115) 0.045*
Glycated haemoglobin (%) -0.010 (0.052) -0.010 (0.047) 1.000
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  
* Statistically significant 
 
 
Table 24. Percentage variation of lipid profile in DHA and placebo groups. 
Data are mean (SD)
 
Variable DHA
(n=15)
Placebo
 (n=15)
P§
Total cholesterol (mg/dL) -0.080 (0.172) -0.058 (0.159) 0.624
HDL cholesterol (mg/dL) 0.013 (0.158) 0.050 (0.128) 0.624
LDL cholesterol (mg/dL) -0.076 (0.219) -0.066 (0.215) 0.870
Triglycerides (mg/dL) -0.223 (0.217) -0.258 (0.186) 0.744
Total cholesterol/HDL -0.085 (0.139) -0.100 (0.121) 0.838
TG/ HDL cholesterol -0.189 (0.363) -0.269 (0.285) 0.567
ApoA (mg/dL) 0.004 (0.083) 0.002 (0.087) 0.902
ApoB (mg/dL) 0.001 (0.220) -0.003 (0.225) 1.000
ApoA/ApoB 0.028 (0.124) 0.032 (0.128) 0.838
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  
 
 
 
Table 25. Percentage variation of hepatic function indicators in DHA and 
placebo groups. Data are mean (SD).
 
 
 DHA
(n=15)
Placebo 
(n=15)
P§
ALT (U/L) -0.072 (0.284) -0.104 (0.260) 0.806
AST (U/L) -0.062 (0.139) -0.079 (0.128) 0.595
GGT (U/L) 0.031 (0.318) 0.089 (0.381) 0.806
Steatosis 0.500 (2.121) 1.000 (1.732) 0.700
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  
 
Table 26. Percentage variation of blood pressure and C-reactive protein in 
DHA and placebo groups. Data are mean (SD).
 
 
 DHA
(n=15)
Placebo 
(n=15)
P§
PAS (mmHg) 0.004 (0.119) -0.008 (0.106) 0.838
PAD (mmHg) 0.002 (0.199) 0.013 (0.208) 0.838
C-reactive protein 
(mg/L)
1.589 (3.707) 0.957 (2.880) 0.870
 
§ Statistical significance of difference between groups (Student t test for 
independent data or Mann-Whitney U test).  
 
 
Dietary intake of total energy, macronutrients, fibre, overall glycemic index 
and glycemic load did not differ between groups both at baseline (minimum p 
= 0.131) and after 6 months (minimum p= 0.215)
 
 
10.2 Analysis of Group A (DHA) characteristics at the end of the study 
Average anthropometric parameters (Table 10) of Group A (DHA) after 6 
months resulted as follows: 
- height 1.57 m (SD 0.08)
- weight 72.08 kg (SD 14.64)
- BMI 28.95 kg/m2 (SD 4.33)
- Waist circumference 86.57 cm (SD 9.50)
- Triceps skinfold 31.84 mm (SD 7.07)
The analysis of data recovered from the breakdown of the FFQ (Table 11) 
administered to subjects proved an average caloric intake of 2470.85 kcal/
day (SD 418.62), hereby divided in macronutrients classes: 
- proteins: 20.23% (SD 5.09), 124.55 g (SD 35.01)
- lipids: 25.34% (SD 4.32), 72.28 g (SD 14.03)
- carbohydrates: 53.07% (SD 6.86), 350.97 g (SD 78.22)
As far as the lipids intake in particular is concerned: 
- saturated: 7.61% (SD 1.98), 20.58 g (SD 4.95)
- monounsaturated: 8.38% (SD 1.22), 22.79 g (SD 3.85)
- polyunsaturated: 2.73% (SD 0.77), 7.62 g (SD 3.01).
Average insulnaemia levels resulted equal to 14.07 µU/ml (SD 4.58). 
 
HOMA calculation, as an index of insulin-resistance resulted equal to 3.05 
(SD 1.06) (Table 12).
For what concerns the lipids profile (Table 12) average levels resulted as 
follows:
- Total Cholesterol: 145.80  mg/dL (SD 22.15)
- HDL Cholesterol: 45.73 mg/dL (SD 9.84)
- LDL Cholesterol: 84.13 mg/dL (SD 16.89)
- Triglycerides: 70.60 mg/dl ( SD 15.73)
- Total cholesterol/ HDL: 3.25 (SD 0.50)
- Triglycerides/HDL: 1.61 (SD 0.46)
- ApoA: 107.00 mg/dL (SD 13.03)
- ApoB: 65.66 mg/dL (SD 13.10)
- ApoA/ApoB: 1.66 mg/dL (SD 0.24)
Average levels of hepatic function indexes (Table 12) resulted as follows: 
- ALT: 25.73 U/L (SD 9.68)
- AST: 24.33 U/L (SD 6.42)
- GGT: 13.73 U/L (SD 6.76)
Arterial pressure detection showed average levels of systolic arterial pressure 
of 115.53 mmHg (SD 10.48) and of diastolic arterial pressure of 66.73 mmHg 
(SD 11.43) (Table 12).
 
10.3 Analysis of Group B (placebo) characteristics at the end of the study
Average anthropometric parameters (Table 14) of Group B (placebo) after 6 
months resulted as follows: 
- height 1.57 m (SD 0.08)
- weight 73.54 kg (SD 15.49)
- BMI 29.18 kg/m2 (SD 4.47)
- Waist circumference 86.80 cm (SD 9.76)
- Triceps skinfold 31.54 mm (SD 7.25)
The analysis of the data recovered from the FFQ breakdown (Table 15) 
administered to subjects showed an average caloric intake of 2416.55 kcal/
day (SD 474.84), hereby divided in macronutrients classes:
- proteins: 20.73% (SD 5.35), 124.54 g (SD 36.95)
- lipids: 25.90% (SD 5.04), 72.20 g (SD 14.81)
- carbohydrates: 52.82% (SD 7.51), 336.38 g (SD 90.60)
As far as the lipids intake in particular is concerned: 
- saturated: 7.71% (SD 2.10), 20.30 g (SD 5.24)
- monounsaturated: 8.27% (SD 1.22), 21.97 g (SD 4.12)
- polyunsaturated: 2.78% (SD 0.77), 7.64 g (SD 3.18)
 
Average insulinaemia levels resulted equal to 7.54 µU/ml (SD 5.07). Mean 
HOMA was 3.84 (SD 1.46) (Table 16).
For what concerns the lipids profile (Table 16) average levels resulted as 
follows: 
- Total Cholesterol: 150.40  mg/dL (SD 19.10)
- HDL Cholesterol: 49.26 mg/dL (SD 10.13)
- LDL Cholesterol: 84.46 mg/dL (SD 16.68)
- Triglycerides: 68.20 mg/dl ( SD 17.20)
- Total Cholesterol/ HDL: 3.13 (SD 0.55)
- Triglycerides/HDL: 1.46 (SD 0.27)
- ApoA: 108.73 mg/dL (SD 13.58)
- ApoB: 66.06 mg/dL (SD 12.87)
- ApoA/ApoB: 1.67 mg/dL (SD 0.27)
Hepatic function average index levels (Table 16) resulted as follows:
- ALT: 26.26 U/L (SD 11.73)
- AST: 25.06 U/L (SD 7.48)
- GGT: 15.06 U/L (SD 8.92)
Arterial pressure detection showed average systolic arterial pressure levels 
equal to 116.47 mmHg (SD 9.27) and of diastolic arterial pressure equal to 
67.20 mmHg (SD 10.57) (Table 16).
 
 
10.4 Overall analysis of data concerning the two groups (DHA and placebo) 
after 6 months
Anthropometric parameters:
- Reduction of BMI and BMI z-score was near to statistical significance 
in children supplemented with DHA (BMI, p =0.088;  BMI z-score, p 
=0.073) but not in the placebo group (minimum p = 0.198) (Table 20); 
- In groups, waist circumference and triceps skinfold measures did not 
show statistically significant variations (Table 17).
 
Diet
- Variation of caloric intake was not statistically significant in either 
groups; 
- Protein intake showed a statistically significant increase both for 
group A (DHA) (p = 0.007) and for Group B (placebo) (p = 0.011), the 
registered increase specifically concerned proteins of animal origin; 
- Lipids intake showed a statistically significant reduction for both 
groups (Group A p = 0.012; Group B p = 0.050), concerning in 
particular the monounsaturated fraction (Group A p = 0.028; Group B 
 
p = 0.021)
- Carbohydrates intake did not show a statistically significant variation 
in either group.
- Dietary intake of total energy, macronutrients, fibre, overall glycemic 
index and glycemic load were comparable between group both at 
baseline and after 6 months. 
 
Carbohydrates profile
- Plasma glucose: both groups showed a statistically significant 
tendency towards a reduction of average fasting plasma glucose 
(Group A p=0.054, Group B p=0.059)
- Insulin: both groups showed a statistically significant reduction of 
average fasting insulinaemia levels (Group A p= 0.001, Group B 
p =0.048) (Table 18). Such improvement is also shown in table 23 
where for the said value a negative percentage variation is identified. 
Insulin average values vary between 21.52 µU/ml (SD 6.85), at the 
beginning of the study, and 14.07 µU/mL (SD 4.58), on termination 
of the study in Group A subjects (DHA). Subjects supplemented 
with placebo showed a variation of insulinaemia values between 
22.13 µU/ml (SD 6.96) and 17.54 µU/ml (SD 5.07). Table 18 shows 
a statistically significant difference for the reduction of insulinaemia 
values in patients supplemented DHA, in comparison to subjects 
supplemented the placebo (p=0.050).
- HOMA (insulin-resistance index): both groups showed a statistically 
significant reduction of average fasting HOMA values (Group A p= 
0.001, Group B p= 0.050). Such improvement is also shown in table 
23 where a negative percentage variation value for the said index 
is identified. Moreover a statistically significant tendency towards 
an improvement of HOMA index (p=0.101) can be highlighted in 
subjects supplemented with DHA in comparison to that identified in 
patients supplemented with the placebo. (Table 18).
 
 
 
 
 
 
 
Lipid profile
 
- Total cholesterol: both groups showed a statistically significant 
decrease (Group A p= 0.031, Group B p= 0.041);
- LDL: both groups presented a statistically significant tendency 
towards a decrease (Group A p= 0.061, Group B p= 0.069);
- HDL: group B showed a statistically significant tendency towards 
increase (Group B p= 0.094);
- Triglycerides: both groups showed a statistically significant decrease 
(Group A p= 0.002, Group B p= 0.001);
- Total cholesterol/HDL: both groups showed a statistically significant 
decrease (Group A p= 0.041, Group B p =0.012);
- Triglycerides/HDL: both groups showed a statistically significant 
decrease (Group A p= 0.020, Group B p= 0.004);
- Apo A and Apo B: no statistically significant variation;
- ApoA/ApoB: both groups showed a statistically significant tendency 
towards decrease (Group A p= 0.078, Group B p= 0.078) (Table 19).
 
Hepatic function indicators
- ALT: no statistically significant variation in either groups;
- AST: statistically significant tendency towards decrease for Group A 
(p= 0.081), statistically significant decrease for Group B (p= 0.016);
- GGT: no statistically significant variation in either groups (Table 20).
 
Arterial Pressure
No statistically significant variation in either groups (Table 21). 
 
Ultrasound profile
No statistically significant variation after 6 months (Table 9 and 13).
 
 
 
 
11. DISCUSSION
The analysis of anthropometric parameters showed a statistically significant 
increase of height as opposed to a steadiness of weight for both groups. As 
far as BMI is concerned, a statistically significant tendency towards decrease 
was observed in the group supplemented with DHA. The latter allows us 
to state that the suggested nutritional intervention did not have a negative 
influence on growth. 
FFQ breakdown analysis showed, from the very early stages, strongly 
inappropriate nutritional habits, characterized by a higher caloric intake than 
what recommended for age and sex. In particular, there were evidences of an 
excessive intake of proteins and lipids at the expense of the carbohydrates 
intake. The comparison with the nutritional analysis after 6 months did not 
show statistically significant variations, especially regarding the caloric 
intake. A statistically significant tendency was registered concerning lipids 
(reduction) and proteins (slight increase). The absence of significant data 
implies the difficulty to modify the nutritional habits of the child and of the 
family, which was the goal of our educational intervention. A statistically 
significant reduction of fasting plasma glucose levels was registered for both 
groups. 
Table 18 shows in details how the insulin-resistance profile improvement 
was greater in those subjects supplemented with DHA in comparison to 
those who were administered the placebo. The latter improvements, for both 
insulinaemia and HOMA, insulin-resistance index, are also accentuated by 
the evaluation of variation percentages values reported in table 23. 
The effect of DHA on insulin-sensitivity can be related to its ability to 
increase the expression of the genes involved in insulin sensitivity and in 
the intercellular transport of glucose, as literature has already described 
(Woodman RJ et al., 2002). 
As far as the lipid profile, despite at the beginning it appeared normal, 
a statistically significant reduction was found of total cholesterol and 
triglycerides values in both groups as well as a statistically significant 
tendency towards decrease for cholesterol/LDL values. The ratios Total 
cholesterol/HDL and Triglycerides/HDL resulted statistically significantly 
reduced for both groups. No variations were reported concerning ApoA and 
ApoB levels, besides a statistically significant tendency to increase their ratio 
in both groups. As these effects were registered equally from both groups, 
they became secondary to the slight reduction of lipid intake observed after 6 
months. 
Concerning liver steatosis, data did not show any variation in the ultrasound 
check profile at the end of the study. The latter contrasts with recent studies 
 
reported in literature which following a supplementation of DHA for 6 months 
proved a slight reduction of hyperecogenicity (Morales AE & Rosenbloom AL, 
2004). 
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12. CONCLUSIONS
Obesity is a serious public health issue both at adult and paediatric age. The 
cornerstones for an intervention on the child are modifying nutritional habits 
and educating to a non-sedentary lifestyle. 
Prostaglandins derived from LCPUFA, play an essential role in adipocyte 
differentiation (Reginato MJ et al., 1998). In adulthood the influence of fatty 
acids on obesity-related complications has been repeatedly studied (Galgiani 
JE et al., 2008; ; U.S. Department of Agricolture and U.S. Department of 
Health and Human Services, 2010), whilst at paediatric age results have 
always been contradictory (Decsi T et al., 1998; Ailhaud G & Guesnet P, 
2004; Okada T et al., 2005). 
Through the present study we tried to evaluate whether the dietary 
supplementation of DHA could have further benefits than a solely nutritional 
and behavioural therapy. The data collected proved an improvement of 
glucose and lipid profiles in both groups, in the one supplemented with DHA 
as well as in the one administered the placebo. However the improvement 
of the insulin-resistance condition resulted greater in subjects supplemented 
with DHA than in the ones taking the placebo. 
The reduction of insulinaemia levels and of the HOMA index which was also 
reported for group B (placebo) should be connected to the dietary nutritional 
intervention and to the encouragement of physical activity. This confirms how 
the nutritional and behavioural approaches must always be the primary ones 
when dealing with an obese child. Therefore, despite the supplementation 
of DHA did improve the insulin-resistance profile, it should anyhow be 
considered as an auxiliary means when treating the main obesity-related 
metabolic complications (insulin-resistance and liver steatosis).
The present study did not prove any effect of reduction on the liver steatosis 
profile. A limit of this study could depend on the duration of the examination 
period, indeed 6 months may not be sufficient to highlight the long-term 
efficacy of liver steatosis treatment. Moreover, the limited sample used for 
the study should be considered a further limitation to it. Furthermore as there 
were no negative evidences caused by the supplementation of DHA, this 
would suggest that a new study could be planned increasing the dosage of 
DHA, to study its long-term effects. 
In conclusion, the present randomized double-blinded study proved the 
effects of DHA on insulin-resistance, but the same were not reported for liver 
steatosis. 
In consideration of such evidences, it is therefore necessary to continue 
the study increasing the sample number, lengthening the duration of the 
observation period and assessing the hypothesis for a further study on DHA 
 
supplementation with higher dosages.
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13. GLOSSARY
 
α-linoleic acid. α-linoleic acid is an organic compound found in many 
common vegetable oils. In terms of its structure, it is named all-cis-9,12,15-
octadecatrienoic acid. In physiological literature, it is given the name 18:3 
(n−3). α-Linolenic acid is a carboxylic acid with an 18-carbon chain and three 
cis double bonds. The first double bond is located at the third carbon from 
the methyl end of the fatty acid chain, known as the n end. Thus, α-linolenic 
acid is a polyunsaturated n−3 (omega-3) fatty acid. It is an isomer of gamma-
linolenic acid, a polyunsaturated n−6 (omega-6) fatty acid.
 
Acanthosis nigricans. Acanthosis nigricans is a brown to black, poorly defined, 
velvety hyperpigmentation of theskin. It is usually found in body folds, such 
as the posterior and lateral folds of the neck, the axilla, groin, umbilicus, 
forehead, and other areas. It typically occurs in individuals younger than 
age 40, may be genetically inherited, and is associated with obesity or 
endocrinopathies, such as hypothyroidism or hyperthyroidism,acromegaly, 
polycystic ovary disease, insulin-resistant diabetes, or Cushing's disease
 
Adiposity rebound. Adiposity rebound is the time at the minimum (nadir) body 
mass index of children, usually occurring at about 5-6 years of age.
 
Apolipoproteins. Apolipoproteins are proteins that bind lipids (oil-soluble 
substances such as fat andcholesterol) to form lipoproteins. They transport 
the lipids through the lymphatic andcirculatory systems.  There are two main 
classes, Apolipoprotein A, the major protein component of high-density 
lipoproteins, and Apolipoproteins B form low-density lipoprotein particles.
 
Arachidonic acid. Arachidonic acid (20:4 n-6, AA)  is a polyunsaturated 
omega-6 fatty acid20:4(ω-6). It is the counterpart to the saturated arachidic 
acid found in peanut oil, (L. arachis – peanut). In chemical structure, 
arachidonic acid is a carboxylic acid with a 20-carbon chain and four cis-
double bonds. Arachidonic acid is a polyunsaturated fatty acid present in the 
phospholipids of membranes of the body's cells.
 
 
Body Mass Index. Body Mass Index (or Quetelet index, BMI) is a heuristic 
proxy for estimating human body fat based on an individual's weight and 
height. Body mass index is defined as the individual's body mass divided 
by the square of his/her height.  The universally used unit of measure in 
medicine is kg/m2.
 
Docosahexaenoic acid. Docosahexaenoic acid (22:6 n-3, DHA) is an omega-3  
fatty acidpolyunsaturated that is a primary structural component of the human 
brain, cerebral cortex, skin, sperm, testicles and retina. It can be synthesized 
from alpha-linolenic acid or obtained directly from maternal milk or fish oil. 
DHA's structure is a carboxylic acid(~oic acid) with a 22-carbon chain cis 
double bonds,  the first double bond is located at the third carbon from the 
omega end. 
 
Eicosapentaenoic acid. Eicosapentaenoic acid (20:5 n-3, EPA) is an omega-
3  fatty acidpolyunsaturated. In chemical structure, EPA is a carboxylic 
acid with a 20-carbon chain and five cis double bonds; the first double 
bond is located at the third carbon from the omega end. EPA and its 
metabolites act in the body largely by their interactions with the metabolites 
of arachidonic acid. EPA acts as a precursor for prostaglandin-3 (which 
inhibits plateletaggregation), thromboxane-3, and leukotriene-5 groups 
(alleicosanoids).
 
Essential fatty acids. Fatty acids that are required by the human body but 
cannot be made in sufficient quantity from other substrates, and therefore 
must be obtained from food, are called essential fatty acids. There are two 
series of essential fatty acids: one has a double bond three carbon atoms 
removed from the methyl end; the other has a double bond six carbon atoms 
removed from the methyl end. Humans lack the ability to introduce double 
bonds in fatty acids beyond carbons 9 and 10, as counted from the carboxylic 
acid side. Two main essential fatty acids are linoleic acid (LA) and alpha-
linolenic acid (ALA). They are widely distributed in plant oils. 
 
Fatty Acids. In chemistry, and especially in biochemistry, a fatty acid is a 
carboxylic acid with a long aliphatic tail (chain), which is either saturated or 
unsaturated. Most naturally occurring fatty acids have a chain of an even 
number of carbon atoms, from 4 to 28. Fatty acids are usually derived from 
triglycerides orphospholipids. When they are not attached to other molecules, 
they are known as "free" fatty acids. Fatty acids are important sources of 
fuel because, when metabolized, they yield large quantities of ATP. Many 
 
cell types can use either glucose or fatty acids for this purpose. In particular, 
heart and skeletal muscle prefer fatty acids. The brain cannot use fatty acids 
as a source of fuel; it relies on glucose or ketone bodies. 
Unsaturated fatty acids have one (mono) or more (poli) double bonds 
between carbon atoms. Saturated fatty acids are long-chain carboxylic acids 
that usually have between 12 and 24 carbon atoms and have no double 
bonds. Thus, saturated fatty acids are saturated with hydrogen. 
Long chain polyunsaturated fatty acid is a fatty acid with aliphatic tails 13 to 
21 carbons.
 
Fatty Liver Disease. Fatty liver disease is a reversible condition where 
large vacuoles of triglyceride fat accumulate in liver cells via the process 
of steatosis (i.e. abnormal retention of lipids within a cell). Despite having 
multiple causes, fatty liver can be considered a single disease that occurs 
worldwide in those with excessive alcohol intake and those who are obese 
(with or without effects of insulin resistance). The condition is also associated 
with other diseases that influence fat metabolism. Morphologically, it is 
difficult to distinguish alcoholic FLD from non-alcoholic FLD, and both show 
microvesicular and macrovesicular fatty changes at different stages. 
 
Food Frequency Questionnaire . Food frequency questionnaires (FFQ) are 
designed to easily assess habitual diet by asking about the frequency with 
which food items or specific food groups are consumed over a reference 
period (e.g. 6 months or a year). They may be based on an extensive 
list of food items or a relatively short list of specific foods. They were 
originally designed to provide descriptive qualitative information about food-
consumption patterns. 
 
Glycemic index. Glycemic index provides a measure of how quickly blood 
sugar levels (i.e. levels of glucose in the blood) rise after eating a particular 
type of food. The glycemic index estimates how much each gram of 
available carbohydrate (total carbohydrate minus fibre) in a food raises a 
person's blood glucose level following consumption of the food, relative to 
consumption of pure glucose. Glucose has a glycemic index of 100.
 
 
Glycemic load. Glycemic load of food estimates how much the food will raise 
a person's blood glucose level after eating it. One unit of glycemic load 
approximates the effect of consuming one gram of glucose. Glycemic load 
accounts for how much carbohydrate is in the food and how much each 
gram of carbohydrate in the food raises blood glucose levels. Glycemic load 
is based on the glycemic index. Glycemic load is defined as the grams of 
available carbohydrate in the food x the food's GI / 100.
 
Hypertension. Hypertension is a chronic medical condition in which the blood 
pressure in the arteries is elevated. Normal blood pressure at rest is within 
the range of 100-140mmHg systolic and 60-90mmHg diastolic. 
 
Homeostasis Model Assessment. Homeostasis Model Assessment (HOMA) 
is a method used to quantify insulin resistance (HOMA-IR) and beta-cell 
function (HOMA-β%). 
 
Insulin-resistance. Insulin-resistance  is a physiological condition in which 
cells fail to respond to the normal actions of the hormone insulin. Insulin job 
is to deliver sugar to cells to provide them with energy. the inverse of insulin 
resistance if the  insulin sensitivity.
 
Linoleic acid. Linoleic acid (18:2 n-6; LA) is an unsaturated n-6 fatty acid 
belonging to one of the two families of essential fatty acids. It is a colourless 
liquid at room temperature. Chemically, linoleic acid is a carboxylic acid with 
an 18-carbon chain and two cis double bonds; the first double bond is located 
at the sixth carbon from the methyl end. 
 
Lipoprotein. A lipoprotein is a biochemical assembly that contains both 
proteins and lipids, bound to the proteins, which allow fats to move through 
the water inside and outside cells. The proteins serve to emulsify the lipid 
(otherwise called fat) molecules. Many enzymes, transporters, structural 
proteins, antigens, adhesins, and toxins are lipoproteins. Examples include 
the high-density (HDL) and low-density (LDL) lipoproteins, which enable 
fats to be carried in the blood stream, the transmembrane proteins of the 
mitochondrion and the chloroplast, and bacterial lipoproteins. 
 
 
Obesity. Obesity is a medical condition in which excess body fat has 
accumulated to the extent that it may have an adverse effect on health. 
Adults are considered obese when their body mass index (BMI), a 
measurement obtained by dividing a person's weight in kilograms by the 
square of the person's height in metres, exceeds 30 kg/m2. For children, the 
International Obesity Task Force recommends using appropriate age- and 
sex-adjusted BMI curves, and defines obesity over the curve having value 30 
kg/m2 at the age of 18 years.
 
Peroxisome proliferator-activated receptor. In the field of molecular biology, 
the peroxisome proliferator-activated receptors (PPARs) are a group of 
nuclear receptor proteins that function as transcription factors regulating 
the expression of genes. PPARs play essential roles in the regulation of 
cellular differentiation, development, and metabolism (carbohydrate, lipid, 
protein), and tumorigenesis of higher organisms. Three types of PPARs have 
been identified: alpha, gamma, and delta (beta). Alpha is expressed in liver, 
kidney, heart, muscle, adipose tissue, and others; Gamma is expressed in 
three forms, including  heart, muscle, colon, kidney, pancreas, and spleen, in 
adipose tissue (30 amino acids longer) macrophages, large intestine, white 
adipose tissue; Delta/Beta is expressed in many tissues but markedly in 
brain, adipose tissue, and skin 
 
Quantitative Insulin-Sensitivity Check Index. Quantitative Insulin-Sensitivity 
Check Index (QUICKI) is an indicator of insulin sensitivity that is derived 
using the inverse of the sum of the logarithms of the fasting insulin and 
fasting glucose. This index has the advantage of that it can be obtained 
from a fasting blood sample, and is the preferred method for certain types of 
clinical research.
 
Transaminase. In biochemistry, a transaminase or an aminotransferase is 
an enzyme that catalyzes a type of reaction between an amino acid and 
an α-keto acid. Two important transaminase enzymes are serum aspartate 
transaninase (AST) and alanine transaminase (ALT). 
 
 
 
 
RIASSUNTO
 
INTRODUZIONE: L’obesità infantile è una patologia di sempre maggior 
interesse, in cui vi è un’elevata prevalenza di insulino-resistenza, quale 
complicanza metabolica. I bambini obesi rispetto ai normopeso evidenziano 
un significativo incremento dei valori plasmatici di LCPUFA della serie n-
6 e più bassi livelli di DHA associati. Diversi studi condotti su adulti hanno 
mostrato che bassi livelli di  DHA, e un elevato rapporto n-6/n-3 LCPUFA  nei 
fosfolipidi di membrana a livello del muscolo scheletrico sono stati associati 
all’insulino-resistenza.
SCOPO: primario: verificare se la supplementazione con DHA, in 
associazione ad un intervento nutrizionale- comportamentale, presenti 
un’efficacia maggiore nel migliorare l’insulino-resistenza, rispetto al solo 
intervento nutrizionale, in bambini affetti da obesità essenziale. Secondario: 
verificare se  il miglioramento della steatosi epatica sia associato alla 
supplementazione con DHA.
SOGGETTI E METODI: si tratta di uno studio longitudinale randomizzato in 
doppio cieco iniziato il 1 Gennaio 2010. Fino al 30 Settembre 2012 sono stati 
reclutati 30 bambini, di cui 14 maschi e 16 femmine di età compresa tra 8-13 
anni, affetti da obesità essenziale, definita secondo i criteri dell’International 
Obesity Task Force (IOTF), giunti alla nostra osservazione presso 
l’Ambulatorio di Nutrizione Clinica della Clinica Pediatrica dell’Ospedale S. 
Paolo di Milano e a quella della Clinica Pediatrica dell’Ospedale Federico 
II di Napoli. I bambini sono stati sottoposti ad intervento nutrizionale-
comportamentale e sono stati randomizzati in due gruppi:
1) Gruppo A: soggetti supplementati con DHA (derivato algale) al 
dosaggio di 500 mg/die,
2) Gruppo B: soggetti supplementati con olio di germe di grano 
(placebo).
Il dosaggio del DHA è stato stabilito in modo da fornire 2.4 grammi di DHA/
1000 Kcal, ovvero il 2 % circa del fabbisogno calorico giornaliero. 
Prima della supplementazione (basale) e dopo 6 mesi sono state effettuate 
le seguenti valutazioni: esame clinico e valutazione della crescita (P, H, BMI, 
circonferenza vita, plica tricipitale, PA), valutazione nutrizionale mediante 
questionario delle frequenze alimentari (FFQ), esami ematochimici (glicemia, 
insulinemia, profilo lipidico, funzionalità epatica), ECG, ecografia  epatica
RISULTATI: al basale i due gruppi (A e B) non hanno presentato tra loro 
differenze statisticamente significative per le variabili considerate nello studio. 
Al termine dello studio entrambi i gruppi hanno mostrato una riduzione 
statisticamente significativa dell’insuline e dell’HOMA. Il miglioramento 
 
del quadro di insulino-resistenza risulta essere maggiore nel gruppo 
supplementato con DHA rispetto al gruppo placebo. In entrambi i gruppi 
si è verificata una riduzione della % di soggetti affetti da steatosi epatica: 
nel gruppo A è passata dal 14% al 7% (P=0.655), nel gruppo B dal 20% al 
13% (P=0.275). Il miglioramento non è risultato differente dal punto di vista 
statistico tra i due gruppi (P=0.775).
CONCLUSIONI: i cardini d’intervento nel bambino obeso sono la 
modificazione delle abitudini alimentari e l’educazione alla non sedentarietà: 
stili di vita adeguati sono in grado non solo di ridurre l’eccesso ponderale, 
ma anche di migliorare il profilo glucidico-insulinemico, come osservato 
nel gruppo placebo. Il nostro studio ha però evidenziato come la 
supplementazione con DHA possa giocare un ruolo importante sullo stato 
di insulino-resistenza, riducendo i livelli di insulinemia e dell’indice ad essa 
correlato (HOMA) maggiormente rispetto al sono intervento nutrizionale. 
Per quanto riguarda l’effetto sulla steatosi epatica, non è stato evidenziato 
alcuna differenza tra i due gruppi, placebo e supplementato con DHA. 
Sono necessari ulteriori studi di adeguata numerosità per valutare gli 
effettivi vantaggi della supplementazione con DHA in aggiunta all’intervento 
nutrizionale sulle principali complicanze metaboliche dell’obesità in età 
pediatrica.
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